



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Adrenocortical tumors have a distinct long non-coding RNA expression profile and LINC00271 is downregulated in malignancy

Citation for published version:

Buishand, F, Liu-Chittenden, Y, Fan, Y, Tirosh, A, Gara, S, Patel, D, Meerzaman, D & Kebebew, E 2019, 'Adrenocortical tumors have a distinct long non-coding RNA expression profile and LINC00271 is downregulated in malignancy', *Surgery*. <https://doi.org/10.1016/j.surg.2019.04.067>

Digital Object Identifier (DOI):

[10.1016/j.surg.2019.04.067](https://doi.org/10.1016/j.surg.2019.04.067)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Surgery

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Manuscript Number: 19-AAES-22R2

Title: Adrenocortical tumors have a distinct long non-coding RNA expression profile and LINC00271 is downregulated in malignancy

Article Type: AAES Society Paper

Section/Category: Basic Research

Keywords: LINC00271; adrenocortical; long noncoding RNA; microarray; prognostic marker; gene signaling pathway.

Corresponding Author: Dr. Floryne Buishand, DVM, PhD, MRCVS

Corresponding Author's Institution: University of Edinburgh

First Author: Floryne Buishand, DVM, PhD, MRCVS

Order of Authors: Floryne Buishand, DVM, PhD, MRCVS; Yi Liu-Chittenden, PhD; Yu Fan, MS; Amit Tirosh, MD; Sudheer Gara, PhD; Dhaval Patel, MD, FACS; Daoud Meerzaman, PhD; Electron Kebebew, MD, FACS

Manuscript Region of Origin: USA

Abstract: Background: Adrenocortical carcinoma (ACC) is an aggressive malignancy with a low but variable overall survival rate. The role of long noncoding RNAs (lncRNAs) in ACC is poorly understood. Thus, in this study we performed lncRNA expression profiling in ACC, adrenocortical adenoma (ACA) and normal adrenal cortex (NAC).

Methods: LncRNA expression profile, using ArrayStar Human LncRNA/mRNA Expression Microarray V3.0, was analyzed in 11 ACA, 9 ACC and 5 NAC samples. Differentially expressed lncRNAs were validated using TaqMan real-time quantitative PCR with additional samples. The ACC Cancer Genome Atlas (TCGA) project dataset was used to evaluate the prognostic utility of lncRNAs.

Results: Unsupervised hierarchical clustering showed distinct clustering of ACC samples compared with NAC and ACA samples by lncRNA expression profiles. A total of 874 lncRNAs were differentially expressed between ACC and NAC. LINC00271 expression level was associated with prognosis, patients with low LINC00271 expression survived shorter than patients with high LINC00271 expression. Low LINC00271 expression was positively associated with WNT signaling, cell cycle, and chromosome segregation pathways.

Conclusions: ACC has a distinct lncRNA expression profile. LINC00271 is downregulated in ACC and is involved in biological pathways commonly dysregulated in ACC.

March 28th, 2019

Kevin E. Behrns, MD and Michael G. Sarr, MD
Editors-in-Chief
Surgery

Dear Editors,

We would like to thank the editors and reviewers again for their time reviewing the manuscript and their helpful comments. We have addressed the comments and believe the manuscript should now meet all requirements set out by the reviewers. Changes are highlighted using track changes in the revised manuscript.

We look forward to hearing your decision.

Sincerely,

A handwritten signature in black ink, appearing to read 'Floryne O. Buishand', with a long horizontal flourish extending to the left.

Floryne O. Buishand, DVM, PhD, MRCVS

AUTHORS' RESPONSE TO REVIEWER'S COMMENTS

We sincerely appreciate the reviewers providing constructive comments. We have made changes that are highlighted in yellow in the manuscript and have addressed all issues raised by the reviewers. Below are the specific responses (in **bold** type) to the Reviewers' comments.

Reviewer 2

The authors have substantially corrected the manuscript and addressed adequately all the prior reviewer concerns. The paper is much improved and acceptable for publication.

We are delighted to read that you believe that our manuscript is acceptable for publication. Once more we would like to thank you for your thoughtful review and useful comments.

Reviewer 3

Improved manuscript after deleting claims that LINC00271 is prognostic in the title and body on manuscript. I would still ask that in the abstract results, the authors delete the word "significantly" (results line 5) which implies statistical validity. Based on the scatter gram plot of survival vs. expression with an r value of 0.5; I think the issue is not proven. I am not convinced of an association of survival. I would defer to statistical review by editorial staff.

Once more thank you for you time to review our manuscript. As per your suggestion we have deleted the word "significantly" in the abstract results.

Recorder Notes

Thank you for making substantial improvements in the manuscript. Please make the revisions requested by reviewer #3. Final acceptance by senior editors is not assured until statistical review as requested.

We have made the revision requested by reviewer #3 as we have deleted the word "significantly" from the abstract results.

1
2
3
4 **Adrenocortical tumors have a distinct long non-coding RNA expression profile and**
5
6 **LINC00271 is downregulated in malignancy***
7
8
9

10 Floryne O. Buishand, DVM, PhD, MRCVS^{1,2}, Yi Liu-Chittenden, PhD¹, Yu Fan, MS³, Amit
11
12 Tirosh, MD⁴, Sudheer K. Gara, PhD¹, Dhaval Patel, MD, FACS^{1,5}, Daoud Meerzaman, PhD³,
13
14 Electron Kebebew, MD, FACS^{1,6}
15
16
17

18
19 ¹Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

20 ²Department of Small Animal Surgery, Royal (Dick) School of Veterinary Studies, The
21 University of Edinburgh, Edinburgh, UK

22 ³Computational Genomics and Bioinformatics Group, Center for Biomedical Informatics and
23 Information Technology, National Cancer Institute, Rockville, MD, USA

24 ⁴Neuroendocrine Tumors Service, Endocrine Institute, Sheba Medical Center, and Sackler
25 Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

26 ⁵Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA

27 ⁶Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, CA, USA
28
29
30
31

32 *Presented at the 40th Annual Meeting of the American Association of Endocrine Surgeons, Los
33
34 Angeles, CA, USA, April 7-9, 2019
35
36
37
38

39 *Corresponding author*

40
41
42 Floryne O. Buishand, DVM, PhD, MRCVS

43
44 The Royal (Dick) School of Veterinary Studies and The Roslin Institute

45
46 Easter Bush Campus, Midlothian, EH25 9RG

47
48
49 United Kingdom

50
51
52 Ph: + 44 131 650 6079

53
54
55 E: Floryne.Buishand@ed.ac.uk
56
57
58
59
60
61
62
63
64
65

1
2
3
4 **Abstract**
5

6 *Background:* Adrenocortical carcinoma (ACC) is an aggressive malignancy with a low but
7
8 variable overall survival rate. The role of long noncoding RNAs (lncRNAs) in ACC is poorly
9
10 understood. Thus, in this study we performed lncRNA expression profiling in ACC,
11
12 adrenocortical adenoma (ACA) and normal adrenal cortex (NAC).
13
14

15
16 *Methods:* lncRNA expression profile, using ArrayStar Human lncRNA/mRNA Expression
17
18 Microarray V3.0, was analyzed in 11 ACA, 9 ACC and 5 NAC samples. Differentially expressed
19
20 lncRNAs were validated using TaqMan real-time quantitative PCR with additional samples. The
21
22 ACC Cancer Genome Atlas (TCGA) project dataset was used to evaluate the prognostic utility of
23
24 lncRNAs.
25
26

27
28 *Results:* Unsupervised hierarchical clustering showed distinct clustering of ACC samples
29
30 compared with NAC and ACA samples by lncRNA expression profiles. A total of 874 lncRNAs
31
32 were differentially expressed between ACC and NAC. *LINC00271* expression level was
33
34 associated with prognosis, patients with low *LINC00271* expression survived ~~a~~-significantly
35
36 shorter ~~time~~ than patients with high *LINC00271* expression. Low *LINC00271* expression was
37
38 positively associated with WNT signaling, cell cycle, and chromosome segregation pathways.
39
40
41

42
43 *Conclusions:* ACC has a distinct lncRNA expression profile. *LINC00271* is downregulated in
44
45 ACC and is involved in biological pathways commonly dysregulated in ACC.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Introduction

Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with an annual incidence of 0.7–2.0 cases per million people and a five-year overall survival rate ranging from 32% to 47%).^{1,2} Furthermore, even after complete tumor resection, over half of the patients develop recurrent disease.³ Patients with locally advanced and metastatic ACC often undergo therapy, which consists of a regimen, including adrenolytic mitotane plus combination chemotherapy with etoposide, doxorubicin, and cisplatin. Unfortunately, this regimen has very limited therapeutic benefit.⁴ The role of adjuvant therapy for ACC is controversial because of questionable therapeutic benefit of current agents and the heterogenous prognosis.³ Understanding the mechanism behind ACC initiation and progression could help in identifying diagnostic and prognostic markers, and therapeutic targets.

Several genomic studies of ACC have reported on distinct ACC genome-wide gene expression, micro-RNA expression, methylation and copy number alteration profiles compared with adrenal cortical adenomas (ACAs) and normal adrenal cortex (NAC).⁵⁻¹⁰ These studies have led to the molecular classification of ACC that is relevant for predicting prognosis. Recently, long noncoding RNAs (lncRNAs) have been suggested to be dysregulated in ACC.¹¹ LncRNAs are RNA transcripts longer than 200 nucleotides that do not encode protein and are localized in the cell nucleus or cytoplasm.¹² The expression of lncRNAs is more tissue specific than protein-coding genes and they function as decoys, scaffolds and enhancer RNAs and are involved in chromatin remodeling, as well as transcriptional and post-transcriptional regulation.¹³

To our knowledge, the study by Glover and colleagues has been the only study that has investigated lncRNA expression profile in ACCs, ACAs and NAC.¹¹ They reported that the highest number of differentially expressed lncRNAs were between ACAs and NAC, with almost 3-fold less lncRNAs being differentially expressed between ACCs and NAC. This finding

1
2
3
4 suggested that changes in lncRNA expression could be an early event in the pathogenesis of both
5
6 ACC and ACAs. However, this finding is in contrast to previous genome-wide analysis results
7
8 that demonstrated a multistep progression in ACC, with increasing genomic changes from NAC
9
10 to ACA to ACC.⁸ Therefore, to further our knowledge of the role of lncRNA in ACCs, we
11
12 performed lncRNA expression profiling using lncRNA microarrays to identify differentially
13
14 expressed lncRNAs in ACCs compared with NACs and ACAs. We also investigated whether
15
16 lncRNA expression levels were associated with ACC overall survival times.
17
18
19
20
21
22

23 **Materials and methods**

24 *Tissue samples*

25
26
27
28 Patients' tumor tissues were procured after informed consent for genetic studies on an
29
30 Institutional Review Board-approved procurement clinical protocol (NCT01005654 and
31
32 NCT01348698). The tissues were immediately snap frozen in liquid nitrogen and stored at -80°C.
33
34 For this study, we used 11 ACA samples and nine ACC samples. Five normal NACs were
35
36 obtained at the time of organ donation harvesting. These 25 tissue samples were used for lncRNA
37
38 microarray profiling. In addition to these samples, an additional 10 ACC samples were included
39
40 in the quantitative RT-PCR (qRT-PCR) validation (Table 1). Tumors were classified as benign
41
42 when the Weiss criteria scores were less than 3 (all the benign samples included had a Weiss
43
44 score of 0), and tumors were classified as ACC when the Weiss criteria scores were more than or
45
46 equal to 3.¹⁴ Only samples with at least 80% tumor cells were included for analysis.
47
48
49
50
51
52
53
54

55 *RNA extraction*

56
57
58 Total RNA was extracted from fresh frozen tissue samples using an RNeasy Mini Kit
59
60 (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. RNA quality was
61
62
63
64
65

1
2
3
4 assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Englewood, CO, USA).
5
6 Only samples with a minimum RNA integrity number of seven were included for analysis.
7
8
9

10 11 *Microarray profiling*

12
13
14 The ArrayStar Human LncRNA/mRNA Expression Microarray Version 3.0 (ArrayStar,
15
16 Inc., Rockville, MD, USA) was used, which includes 30,586 lncRNA probes and 26,109 coding
17
18 transcripts, for lncRNA profiling. RNA labeling, microarray hybridization, slide washing and
19
20 scanning were performed based on the standard protocols of ArrayStar. Agilent Feature
21
22 Extraction software (version 11.0.1.1) was used to analyze acquired array images. The
23
24 microarray specifications and derived data are accessible through National Center for
25
26 Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) accession number
27
28 GSE124531.
29
30
31
32
33
34
35

36 *TaqMan real-time quantitative PCR*

37
38 RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription kit
39
40 (Applied Biosystems, Foster City, CA, USA). TaqMan qRT-PCR was performed using the
41
42 7900HT fast real-time PCR systems (Applied Biosystems). The reaction contained cDNA,
43
44 TaqMan 2×universal PCR master mix and TaqMan gene expression assays primers (Applied
45
46 Biosystems). LncRNAs were selected for validation based on three criteria: 1) availability of
47
48 validated TaqMan gene expression primer/probe assays, 2) possible role in cancer, and 3)
49
50 magnitude of differential expression. The gene expression assays used were: *HOTTIP*
51
52 (Hs03649396_m1), *CHL1* (Hs04332026_m1), *HOXA11-AS1* (Hs_03454334_g1), *CRNDE*
53
54 (HS04404483_m1), *LINC00271* (Hs03657384_m1), *FAM211A-AS1* (Hs03678558_g1), *TBXAS1*
55
56 (Hs01096058_s1) and *GAPDH* (Hs99999905_m1).
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 *Comparative genomic hybridization (CGH) array analysis*
8

9 We used our previously published genome-wide CGH array data in a cohort of NAC,
10 ACA, and ACC.⁸ The *LINC100271* site was manually scanned for its copy number status using
11 Nexus software.
12
13
14

15
16
17
18
19 *Statistical and data analysis*
20

21 LncRNA expression profiles of ACC samples were compared with NAC and ACA
22 samples. The Gaussian linear model was used to calculate *P*-values, and false discovery rates
23 (FDRs) were calculated using the Benjamini-Hochberg method for each lncRNA. LncRNAs with
24 log₂ fold change ≥ 2 and FDR < 0.05 were defined as differentially expressed lncRNAs.
25
26 Differentially expressed lncRNAs were mapped to their associated gene names and then gene set
27 enrichment analysis (GSEA) was performed on these genes. An in-house R package, OmicPath
28 (v 0.1) was used to perform GSEA to discover potential KEGG pathway associations for each set
29 of differentially expressed lncRNAs. Pathways with a *P*-value < 0.05 were considered significant.
30
31 Survival curves were plotted using the Kaplan-Meier methods, and differences in survival rates
32 were determined using the log-rank test. These statistical analyses were done with GraphPad
33 Software and *P* < 0.05 was considered significant.
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 The ACC cohort from the Cancer Genome Atlas (TCGA) project database ([https://tcga-](https://tcga-data.nci.nih.gov/tcga/)
49 [data.nci.nih.gov/tcga/](https://tcga-data.nci.nih.gov/tcga/)) which included 79 patients with *HOTTIP*, *CHL1*, *HOXA11-AS1*, *CRNDE*,
50 *LINC00271*, *FAM211A-AS1* and *TBXAS1* expression data, as well as follow-up information, were
51 used to study the prognostic significance of lncRNAs. For overall survival analysis two groups
52 were defined based on the lncRNA expression levels in the primary tumor. Those with a lncRNA
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 level ranked in the top half were classified into the high expression group and the rest into the
5
6 low expression group based on the median value.
7

8
9 The gene expression profiles of ACC samples deposited in the TCGA project database
10
11 were analyzed to compare expression patterns in tumors with high ($n = 39$) vs. low *LINC100271*
12
13 expression ($n = 40$). The downloaded data consisted of quantified gene expression data, that were
14
15 further processed using the DESeq2 package.¹⁵ The differentially expressed genes were annotated,
16
17 and GSEA analysis was performed using the clusterProfiler package.¹⁶
18
19
20
21
22

23 **Results**

24 *Differentially expressed lncRNAs in ACC versus NAC*

25
26
27
28 Unsupervised hierarchical and heat map clustering showed distinct clustering of ACC
29
30 samples compared with NAC and ACA samples (Fig. 1). Eight hundred and seventy-four
31
32 lncRNAs were differentially expressed in ACC compared with NAC, of which 409 were
33
34 upregulated and 465 were downregulated. The 874 differentially expressed lncRNAs
35
36 corresponded to 330 annotated lncRNA genes. Among the upregulated lncRNAs, the highest
37
38 log₂ fold change was 8.5 for an unannotated lncRNA gene, and *RAD50* was the highest
39
40 upregulated annotated lncRNA gene with a log₂ fold change of 6.1. Among the downregulated
41
42 lncRNAs, the highest log₂ fold change was 8.3 for an unannotated lncRNA gene and 6.4 for
43
44 *HAND2*, the highest downregulated annotated lncRNA gene. One hundred and eighty-three
45
46 differently expressed lncRNAs had established functions in cancer development and cancer
47
48 progression. Selected carcinogenesis-related lncRNAs are summarized in Table 2.
49
50
51
52

53
54
55 To test the validity of the microarray findings, seven lncRNAs (*HOTTIP*, *CHL1*,
56
57 *HOXA11-AS1*, *CRNDE*, *LINC00271*, *FAM211A-AS1* and *TBXAS1*) were selected among the
58
59 carcinogenesis-related differentially expressed lncRNAs and their expression was analyzed by
60
61
62

1
2
3
4 TaqMan qRT-PCR. The validation cohort included 19 ACC samples and 5 NAC samples.
5
6 *HOTTIP*, *HOXA11-AS1* and *CRNDE* were overexpressed in ACC ($P < 0.05$) and confirmed by
7
8 TaqMan qRT-PCR in the validation cohort ($P < 0.05$; Fig. 2). *LINC00271*, *FAM211A-AS1* and
9
10 *TBXAS1* expression was downregulated in ACC ($P < 0.05$) and also by TaqMan qRT-PCR ($P <$
11
12 0.05) (Fig 2). The microarray result for *CHLI* was not confirmed in the validation cohort.
13
14 Upregulated expression of *CHLI* was identified in the microarray analysis ($P < 0.05$) while
15
16 *CHLI* was found to be not significantly upregulated by TaqMan qRT-PCR in the validation
17
18 cohort.
19
20
21
22
23
24
25

26 *Differentially expressed lncRNAs in ACC versus ACA*

27

28 One thousand seventy-six lncRNAs were differentially expressed in ACC compared with
29
30 ACA, of which 780 were upregulated and 296 were downregulated. The 1,076 differentially
31
32 expressed lncRNAs corresponded to 376 annotated lncRNA genes. Among the upregulated
33
34 lncRNAs, the highest log₂ fold change was 8.2 for an unannotated lncRNA and 7.0 for *NKAIN4*,
35
36 the highest upregulated annotated lncRNA. Among the downregulated lncRNAs, the highest log₂
37
38 fold change was 7.1 for an unannotated lncRNA gene and 6.9 for *SSTR5*, the highest
39
40 downregulated annotated lncRNA.
41
42
43
44

45 There was overlap in 206 lncRNAs as they were downregulated in ACC compared to
46
47 NAC and ACC compared to ACA, and 355 lncRNAs overlapped as they were upregulated in
48
49 ACC compared to NAC and ACA (Fig. 3).
50
51
52
53
54

55 *Differentially expressed lncRNAs in ACA versus NAC*

56
57
58
59
60
61
62
63
64
65

1
2
3
4 Unsupervised hierarchical and heat map clustering showed that NAC samples clustered
5
6 together with ACA samples (Fig. 1). Only ten lncRNAs were differentially expressed in ACA
7
8 compared with NAC.
9

10 11 12 13 14 *Functional pathway analysis*

15
16 KEGG pathway analysis of the differentially expressed and annotated lncRNAs in ACC
17
18 compared with NAC and ACC compared with ACA was performed to understand the biological
19
20 relevance of these lncRNAs. Twenty-one pathways were significantly enriched in ACC versus
21
22 ACA and 29 pathways were significantly enriched in ACC versus NAC (Tables 3 and 4). Twelve
23
24 of the altered 21 pathways were common to the comparison of ACC versus ACA and ACC
25
26 versus NAC. The KEGG pathways common to both comparisons included ‘Transcriptional
27
28 misregulation in cancer’ and ‘ECM-receptor interaction’.
29
30
31
32
33
34
35

36 *Prognostic lncRNAs in ACC*

37
38 Using the survival data of the ACC TCGA cohort, the prognostic significance of
39
40 *HOTTIP*, *HOXA11-AS1*, *CRNDE*, *LINC00271*, *FAM211A-AS1* and *TBXAS1* was analyzed. Only
41
42 *LINC00271* expression (Fig. 4A) was found to be associated with prognosis. *LINC00271*
43
44 expression levels was positively associated with survival time (Fig. 4B). Median survival time for
45
46 the low-*LINC00271* expression group ($n = 40$) was 4.9 years, whereas it was not reached for the
47
48 high-*LINC00271* expression group ($n = 39$) ($P < 0.019$) (Fig 4C). Student’s t-tests demonstrated
49
50 that *LINC00271* expression levels of stage I tumors were significantly higher than those of stage
51
52 IV tumors ($P < 0.006$).
53
54
55
56
57
58
59

60 *Identification of LINC00271-associated biological pathways by Gene Set Enrichment Analysis*

61
62
63
64
65

1
2
3
4 To identify *LINC00271*-associated biological pathways, GSEA was performed using high
5
6 throughput RNA-sequencing data from the TCGA ACC cohort. Among the GO gene sets, WNT
7
8 signaling pathway, cell cycle, chromosome segregation and tissue morphogenesis were found to
9
10 be significantly associated with low *LINC00271* expression in the ACC TCGA cohort (Fig. 5),
11
12 suggesting that *LINC00271* may be involved in ACC development and/or progression through
13
14 the above cancer-associated signaling pathways.
15
16
17
18
19
20

21 *LINC00271* copy number alterations

22

23 An analysis of the *LINC00271* chromosomal locus, 6q23.3, using genome-wide CGH
24
25 array data that were previously generated in a cohort of NAC, ACA, and ACC¹⁰, was performed
26
27 to examine whether the *LINC00271* site demonstrated any copy number alterations to explain its
28
29 downregulated expression in ACC. One out of 11 NAC samples demonstrated a deletion at
30
31 6q23.3, whereas 2 of 18 ACA samples demonstrated deletions at 6q23.3 and two other ACA
32
33 samples demonstrated amplifications at 6q23.3. The *LINC00271* locus was most unstable in
34
35 ACCs, with 4 of 19 ACC samples demonstrating deletions and 4 of 19 ACC samples
36
37 demonstrating amplifications of 6q23.3.
38
39
40
41
42
43
44

45 **Discussion**

46

47 This study demonstrated that NAC, ACA and ACC have distinct lncRNA expression
48
49 profiles, and that *LINC00271*, involved in biological pathways commonly dysregulated in ACC,
50
51 is a prognostic marker in ACC.
52
53
54

55 Eight hundred and seventy-four lncRNAs were differentially expressed in ACC compared
56
57 with NAC, 1076 lncRNAs were differentially expressed in ACA compared with ACC, and only
58
59 ten lncRNAs were differentially expressed in ACA vs. NAC. Previously, Glover and colleagues
60
61
62
63
64
65

1
2
3
4 demonstrated that the highest number of differentially expressed lncRNAs in their study were
5
6 between ACA and NAC (2655 lncRNAs), while 956 lncRNAs were differentially expressed
7
8 between ACC and NAC, and 85 lncRNAs were differentially expressed between ACC and
9
10 ACA.¹¹ They suggested that changes in lncRNA expression could be an early part in the
11
12 pathogenesis of both ACC and ACAs. However, our results are not entirely consistent with their
13
14 findings as we found only ten lncRNAs that were differentially expressed between ACA and
15
16 NAC. However, this finding is in line with the multistep hypothesis in tumorigenesis that is
17
18 present in most human cancers - progressive genetic/genomic alterations increasing/accumulating
19
20 from NAC to ACA to ACC as previously described in our integrated genome-wide gene
21
22 expression, gene methylation, microRNA expression and CGH analysis in human NAC, ACA
23
24 and ACC samples.⁸ The multistep progression from NAC to ACA to ACC is further supported by
25
26 our finding of 296 lncRNAs differentially expressed between ACA versus ACC and 465
27
28 lncRNAs differentially expressed between ACC vs. NAC. Overall, we found less differently
29
30 expressed lncRNAs in adrenocortical tumors compared to the Glover et al. study¹¹ but we used a
31
32 more stringent fold change cut-off to identify differentially expressed lncRNAs and the NAC
33
34 samples used in our study were not adjacent normal tissue to ACAs.
35
36
37
38
39
40
41
42

43 In the current study, the TCGA ACC dataset was used to screen for prognostic
44
45 significance of differentially expressed lncRNAs. *LINC00271* was found to be associated with
46
47 malignancy, with patients with low *LINC00271* expression levels surviving a significantly shorter
48
49 time than patients with high *LINC00271* expression levels. Previously, significantly lower
50
51 expression of *LINC00271* has been described in invasive breast carcinoma, lung adenocarcinoma,
52
53 kidney renal papillary cell carcinoma, head and neck squamous cell carcinoma and papillary
54
55 thyroid cancer.¹⁷ In addition, *LINC00271* has been found to be an independent risk factor for
56
57 extrathyroidal extension, lymph node metastasis, advanced tumor stage III/IV and recurrence in
58
59
60
61
62
63
64
65

1
2
3
4 papillary thyroid cancer.¹⁷ GSEA revealed that genes associated with cell adhesion molecules,
5
6 TP53 signaling pathway, JAK/STAT signaling pathway and cell cycle were significantly
7
8 enriched in papillary thyroid cancer with a low *LINC00271* expression versus papillary thyroid
9
10 cancer with higher *LINC00271* expression. We also found that genes associated with cell cycle
11
12 were associated with low *LINC00271* expression in the TCGA ACC cohort. Further *LINC00271*
13
14 expression was positively associated with WNT signaling pathway and chromosome segregation,
15
16 biological pathways commonly dysregulated in ACC.^{18,19} Thus, our findings and other
17
18 investigators studies suggest that *LINC00271* could contribute to abnormal activation of these
19
20 pathways in a tumor suppressor manner, however further mechanistic studies are needed to test
21
22 this hypothesis.
23
24
25
26
27

28
29 Studies have suggested that genes with causal roles in tumorigenesis are often located in
30
31 chromosomal areas with copy number alterations.^{20,21} Gene expression levels are directly
32
33 dependent on chromosomal aneuploidies in carcinomas.²² The strongest correlations have been
34
35 found between genomic copy number and average chromosome-wide expression levels, but the
36
37 expression of individual genes has also been associated with genomic copy numbers.²³ LncRNAs
38
39 expression levels have been positively correlated with copy number alterations as well.^{24,25}
40
41 Therefore, we investigated whether copy number alterations were present at the *LINC00271*
42
43 chromosomal locus, 6q23.3. This region had the highest alteration in ACC samples with 21% of
44
45 samples demonstrating amplifications and another 21% demonstrating deletions, while only 11%
46
47 of ACA samples had amplifications and another 11% deletions of 6q23.3. The instability of
48
49 6q23.3 might explain the dysregulated expression of *LINC00271* in ACC.
50
51
52
53
54

55
56 In conclusion, ACC has a distinct lncRNA expression profile, and *LINC00271*
57
58 downregulation is associated with malignancy and is involved in biological pathways commonly
59
60 dysregulated in ACC.
61
62
63
64
65

1
2
3
4
5
6
7 **Disclosure of interest**

8
9 The authors report no proprietary or commercial interest in any product mentioned or concept
10 discussed in this article.
11
12
13
14

15
16 **Acknowledgements**

17
18 This work was supported by the intramural research program of the Center for Cancer Research,
19 National Cancer Institute, National Institutes of Health (1ZIABC011275-09).
20
21
22
23
24

25
26 **References**

- 27
28
29
30
31 1. Bilmoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, et al.
32 Adrenocortical carcinoma in the United States: treatment utilization and prognostic
33 factors. *Cancer* 2008;113:3130-6.
34
35
36
37
38 2. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, et
39 al. Adrenocortical carcinoma: a population-based study on incidence and survival in the
40 Netherlands since 1993. *Eur J Cancer* 2013;49:2579-86.
41
42
43
44
45 3. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, et al. Recurrence of
46 adrenal cortical carcinoma following resection: surgery alone can achieve results equal to
47 surgery plus mitotane. *Ann Surg Oncol* 2010;17:263-70.
48
49
50
51
52 4. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination
53 chemotherapy in advanced adrenocortical carcinoma. *N Engl J Med* 2012;366:2189-97.
54
55
56
57 5. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, et al. Molecular
58 classification and prognostication of adrenocortical tumors by transcriptome profiling.
59
60
61
62
63
64
65

- 1
2
3
4 Clin Cancer Res 2009;15:668-76.
5
6
7 6. Soon PS, Gill AJ, Benn DE, Clarkson A, Robinson BG, McDonald KL, et al. Microarray
8
9 gene expression and immunohistochemistry analyses of adrenocortical tumors identify
10
11 IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. *Endocr Relat*
12
13 *Cancer* 2009;16:573-83.
14
15
16 7. Rechache NS, Wang Y, Stevenson HS, Killian JK, Edelman DC, Merino M, et al. DNA
17
18 methylation profiling identifies global methylation differences and markers of
19
20 adrenocortical tumors. *J Clin Endocrinol Metab* 2012;97:E1004-13.
21
22
23 8. Gara SK, Wang Y, Patel D, Liu-Chittenden Y, Jain M, Boufraquech M, et al. Integrated
24
25 genome-wide analysis of genomic changes and gene regulation in human adrenocortical
26
27 tissue samples. *Nucleic Acids Res* 2015;43:9327-39.
28
29
30 9. Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O., et al. Integrated
31
32 genomic characterization of adrenocortical carcinoma. *Nat Genet* 2014;46:607-12.
33
34
35 10. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al.
36
37 Comprehensive pan-genomic characterization of adrenocortical carcinoma. *Cancer Cell*
38
39 2016;29:723-36.
40
41
42 11. Glover AR, Zhao JT, Ip JC, Lee JC, Robinson BG, Gill AJ, et al. Long noncoding RNA
43
44 profiles of adrenocortical cancer can be used to predict recurrence. *Endocr Relat Cancer*
45
46 2015;22:99-109.
47
48
49 12. Li L, Chang HY. Physiological roles of long noncoding RNAs: insight from knockout
50
51 mice. *Trends Cell Biol* 2014;24:594-602.
52
53
54 13. Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in
55
56 cancer. *Genomics Proteomics Bioinformatics* 2016;14:42-54.
57
58
59 14. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in
60
61
62
63
64
65

- 1
2
3
4 adrenocortical carcinoma. *Am J Surg Pathol* 1989;13:202-6.
5
6
7 15. Love M, Huber W, Anders S. Moderated estimation of fold change and dispersion for
8
9 RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.
10
11 16. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological
12
13 themes among gene clusters. *OMICS* 2012;16:284-7.
14
15
16 17. Ma B, Liao T, Wen D, Dong C, Zhou L, Yang S, et al. Long intergenic non-coding RNA
17
18 271 is predictive of a poorer prognosis of papillary thyroid cancer. *Sci Rep* 2016;6:36973.
19
20
21 18. Roshani L, Fujioka K, Auer G, Kjellman M, Lagercrantz S, Larsson C. Aberrations of
22
23 centrosomes in adrenocortical tumors. *Int J Oncol* 2002;20:1161-5.
24
25
26 19. Ragazzon B, Libe R, Gaujoux S, Assie G, Fratticci A, Launay P, et al. Transcriptome
27
28 analysis reveals that p53 and b-catenin alterations occur in a group of aggressive
29
30 adrenocortical cancers. *Cancer Res* 2010;70:8276-8281.
31
32
33 20. Kim TM, Xi R, Luquette LJ, Park RW, Johnson MD, Park PJ. Functional genomic
34
35 analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. *Genome*
36
37 *Res* 2013;23:217-27.
38
39
40 21. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, et al. Pan-
41
42 cancer patterns of somatic copy number alteration. *Nat Genet* 2013;45:1134-40.
43
44
45 22. Grade M, Hormann P, Becker S, Hummon AB, Wangsa D, Varma S, et al. Gene
46
47 expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation
48
49 and distinct differences between lymph node-negative and lymph node-positive colon
50
51 carcinomas. *Cancer Res.* 2007;67:41-56.
52
53
54 23. Ried T, Hu Y, Difilippantonio MJ, Ghadimi BM, Grade M, Camps J. The consequences
55
56 of chromosomal aneuploidy on the transcriptome of cancer cells. *Biochim Biophys Acta*
57
58 2012;1819:784-93.
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

24. Chen H, Xu J, Hong J, Tang R, Zhang X, Fang JY. Long noncoding RNA profiles identify five distinct molecular subtypes of colorectal cancer with clinical relevance. *Mol Oncol* 2014;8:1393-403.

25. Deng Y, Luo S, Zhang X, Zou C, Yuan H, Liao G, et al. A pan-cancer atlas of cancer hallmark-associated candidate driver lncRNAs. *Mol Oncol* 2018;12:1980-2005.

Tables

Table 1. Clinical features of ACA and ACC patients

	ACA*	ACC [†] included in microarray	ACC in validation cohort
Number of patients	11	9	10
Age (average ± SD)	46.0 years ± 18.7	52.2 years ± 14.7	46.7 years ± 13.7
Sex (female/male)	9/2	7/2	6/4
Tumor size (average ± SD)	3.8 cm ± 1.8	6.7 cm ± 5.9	5.4 cm ± 2.2
Functional Syndrome[‡]	55%	44%	30%
Adrenal hypercortisolism	3	4	3
Primary hyperaldosteronism	3	1	0
Nonfunctioning	6	4	7

*ACA, adrenocortical adenoma

[†]ACC, adrenocortical carcinoma

[‡]Functional status at initial presentation

Table 2. Selected carcinogenesis-related differentially expressed lncRNAs between ACC and NAC

Sequence name	Gene symbol	Regulation	P-value	Log2 fold change	Chromosome	Relationship
ENST00000534886	<i>SRRM4</i>	Up	0.001	5.14	Chr12	Intron sense-overlapping
ENST00000472494	<i>HOTTIP</i>	Up	9.11 x 10 ⁻⁵	5.05	Chr7	Bidirectional
ENST00000514846	<i>GRK6</i>	Up	9.92 x 10 ⁻⁶	4.75	Chr5	Natural antisense
NR_002795	<i>HOXA11</i>	Up	4.61 x 10 ⁻⁵	4.05	Chr7	Bidirectional
NR_045572	<i>CHLI</i>	Up	3.45 x 10 ⁻⁴	4.16	Chr3	Exon sense-overlapping
ENST00000558031	<i>CRNDE</i>	Up	1.30 x 10 ⁻⁵	2.45	Chr16	Intergenic
ENST00000502941	<i>HAND2</i>	Down	1.52 x 10 ⁻⁷	6.35	Chr4	Bidirectional
ENST00000450445	<i>BNC2</i>	Down	1.36 x 10 ⁻⁶	5.01	Chr9	Intronic antisense
ENST00000417354	<i>DNM3</i>	Down	4.46 x 10 ⁻⁶	3.50	Chr1	Intronic antisense

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

NR_029394	<i>TBXAS1</i>	Down	2.15×10^{-4}	2.51	Chr7	Exon sense- overlapping
NR_026805	<i>LINC00271</i>	Down	3.99×10^{-6}	2.50	Chr6	Bidirectional
NR_027158.1	<i>FAM211A-AS1</i>	Down	2.96×10^{-3}	2.06	Chr17	Intronic antisense

Table 3. Significantly different KEGG pathways in ACC versus ACA

Pathways	Genes	P-value
Pathways in cancer	<i>ADCY2, RALBP1, CSF2RA, DAPK1, FGF13, GSK3B, BIRC5, ITGA3, MMP9, PTGER3, SLC2A1, TGFB2, PAX8, RUNX1</i>	1.791e-3
Vascular smooth muscle contraction	<i>KCNMB2, ADCY2, KCNMA1, AVPRIA, PRKCQ, PRKG1</i>	3.251e-3
Glucagon signaling pathway	<i>ADCY2, PRKAG2, PGAM2, PHKA2, SLC2A1</i>	5.823e-3
Malaria	<i>ITGAL, TGFB2, THBS4</i>	7.960e-3
Transcriptional misregulation in cancer	<i>HOXA10, HOXA11, MMP9, PAX8, HMGA2, HIST1H3G, RUNX1</i>	8.716e-3
Insulin secretion	<i>KCNMB2, ADCY2, KCNMA1, SLC2A1</i>	1.209e-2
Circadian rhythm	<i>ADCY2, PRKG1, PTGER3</i>	1.266 e-2
Salivary secretion	<i>NPAS2, PRKAG2</i>	1.346 e-2
Cell cycle	<i>ADCY2, KCNMA1, LYZ, PRKG1</i>	1.455 e-2
Colorectal cancer	<i>E2F5, GSK3B, MAD2L1, RBL2, TGFB2</i>	1.522 e-2
FoxO signaling pathway	<i>GSK3B, BIRC5, TGFB2</i>	1.786 e-2
Glycolysis / Gluconeogenesis	<i>S1PR1, PRKAG2, RBL2, BNIP3, TGFB2</i>	2.149 e-2
Ubiquitin mediated proteolysis	<i>PGAM2, ADPGK, FBP2</i>	2.307 e-2
Adipocytokine signaling pathway	<i>UBE2S, UBE2D4, SIAH1, UBE2G2, ITCH</i>	2.367 e-2
Signaling pathways regulating pluripotency of stem cells	<i>PRKAG2, PRKCQ, SLC2A1</i>	2.661 e-2
Bladder cancer	<i>ESRRB, GSK3B, PAX6, POU5F1B, PCGF1</i>	2.762 e-2
Insulin resistance	<i>DAPK1, MMP9</i>	2.841 e-2
RNA degradation	<i>GSK3B, PRKAG2, PRKCQ, SLC2A1</i>	3.180 e-2
ECM-receptor interaction	<i>LSM1, EXOSC10, BTG1</i>	3.605 e-2
Hypertrophic cardiomyopathy (HCM)	<i>SV2C, ITGA3, THBS4</i>	4.385e-2

Note Pathways common to the comparison of ACC versus ACA and ACC versus NAC are written in bold type

Table 4. Significantly different KEGG pathways in ACC versus NAC

Pathways	Genes	P-value
ECM-receptor interaction	<i>COL6A2, SV2C, ITGA3, ITGA9, THBS2</i>	5.329e-4
Circadian rhythm	<i>NPAS2, PRKAG2, BHLHE40</i>	5.596e-4
Vascular smooth muscle contraction	<i>MRVII, KCNMA1, AVPR1A, PRKACB, PRKCQ, PRKG1</i>	7.222e-4
Adipocytokine signaling pathway	<i>IKBKB, PRKAG2, PRKCQ, SLC2A1</i>	1.759e-3
Transcriptional misregulation in cancer	<i>HOXA11, MEIS1, MMP9, UTY, PAX8, HMGA2, HIST1H3G</i>	1.785e-3
Cocaine addiction	<i>GRIN3B, GRM3, PRKACB</i>	3.175e-3
Salivary secretion	<i>KCNMA1, LYZ, PRKACB, PRKG1</i>	5.0121e-3
Glucagon signaling pathway	<i>PRKAG2, PGAM2, PRKACB, SLC2A1</i>	8.511e-3
Glycolysis / Gluconeogenesis	<i>ADH1A, PGAM2, ADPGK</i>	9.687e-3
Insulin resistance	<i>IKBKB, PRKAG2, PRKCQ, SLC2A1</i>	1.161e-2
Nicotine addiction	<i>CHRNA4, GRIN3B</i>	1.345e-2
Proteasome	<i>PSMA3, PSMD7</i>	1.740e-2
Platelet activation	<i>LYN, PRKACB, PRKG1, TBXAS1</i>	1.817e-2
Hypertrophic cardiomyopathy (HCM)	<i>ITGA3, ITGA9, PRKAG2</i>	1.998e-2
Hedgehog signaling pathway	<i>CDON, PRKACB</i>	2.074e-2
Endocrine and other factor-regulated calcium reabsorption	<i>DNM3, PRKACB</i>	2.074e-2
Insulin secretion	<i>KCNMA1, PRKACB, SLC2A1</i>	2.161e-2
Neuroactive ligand-receptor interaction	<i>CHRNA4, GRIN3B, GRM3, AVPR1A, RXFP1, SSTR5, THRB</i>	2.227e-2
Dilated cardiomyopathy	<i>ITGA3, ITGA9, PRKACB</i>	2.602e-2
Morphine addiction	<i>GRK6, PDE4D, PRKACB</i>	2.697e-2
NF-kappa B signaling pathway	<i>IKBKB, LYN, PRKCQ</i>	2.891e-2
Circadian entrainment	<i>PRKACB, PRKG1, CACNA1H</i>	3.094e-2
Regulation of lipolysis in adipocytes	<i>PRKACB, PRKG1</i>	3.273e-2
Long-term depression	<i>LYN, PRKG1</i>	3.900e-2
Focal adhesion	<i>COL6A2, ITGA3, ITGA9, PAK3, THBS2</i>	4.064e-2
T cell receptor signaling pathway	<i>IKBKB, PAK3, PRKCQ</i>	4.110e-2
Longevity regulating pathway – multiple species	<i>PRKAG2, PRKACB</i>	4.584e-2
Renin secretion	<i>KCNMA1, PRKACB</i>	4.584e-2
Renal cell carcinoma	<i>PAK3, SLC2A1</i>	4.946e-2

Note Pathways common to the comparison of ACC versus ACA and ACC versus NAC are written in bold type

1
2
3
4 **Figure legends**
5
6
7
8

9 **Fig 1.** Unsupervised hierarchical clustering and heat map of lncRNA expression between
10 adrenocortical carcinoma (ACC), adrenocortical adenoma (ACA) and normal adrenal cortex
11 (NAC). Each column represents a sample and each row represents a lncRNA. High relative
12 expression is indicated in yellow and low relative expression in red.
13
14
15
16
17
18
19
20

21 **Fig 2.** TaqMan qRT-PCR validation of lncRNA microarray analysis. Fold change in comparison
22 of adrenocortical carcinoma versus normal adrenal cortex, * $P < 0.05$.
23
24
25
26
27

28 **Fig 3.** Venn diagram showing the number of overlapping up- or downregulated lncRNAs in the
29 different comparisons. ACC, adrenocortical carcinoma; ACA, adrenocortical adenoma; NAC,
30 normal adrenal cortex.
31
32
33
34
35
36
37

38 **Fig 4.** *LINC00271* expression and prognosis. A, Distribution of *LINC00271* expression of
39 adrenocortical carcinoma samples from the TCGA dataset. Red points were defined as low-
40 *LINC00271* expression group and black points were defined as high-*LINC00271* expression
41 group. B, *LINC00271* expression is positively correlated to survival time (Pearson correlation
42 coefficient = 0.50). C, Kaplan-Meier plot of overall survival in the TCGA adrenocortical
43 carcinoma cohort is shown according to *LINC00271* expression level (low vs. high).
44
45
46
47
48
49
50
51
52
53
54


55 **Fig 5.** *LINC00271*-associated biological signaling pathways. Based on the TCGA dataset, GSEA
56 showed that genes associated with WNT signaling pathway, cell cycle, chromosome segregation
57 and tissue morphogenesis were significantly enriched in lower *LINC00271* versus higher
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

LINC00271 expressing adrenocortical carcinomas. FDR, false discovery rate; NES, normalized enrichment score.

|

Figure 1
[Click here to download high resolution image](#)



ACC6
ACC4
ACC2
ACC3
ACC1
ACC7
ACC8
ACC5
ACC9
NAC4
NAC3
ACA2
ACA1
ACA7
NAC1
NAC5
ACA5
ACA10
ACA6
NAC2
ACA3
ACA4
ACA11
ACA9
ACA8

Figure 2
[Click here to download high resolution image](#)




Figure 3
[Click here to download high resolution image](#)




Figure 4
[Click here to download high resolution image](#)








Figure 5
[Click here to download high resolution image](#)



19-AAES-22R2 EDITED BY DR SARR

**Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and
LINC00271 is downregulated in malignancy***

Floryne O. Buishand, DVM, PhD, MRCVS^{1,2}, Yi Liu-Chittenden, PhD¹, Yu Fan, MS³, Amit
Tirosh, MD⁴, Sudheer K. Gara, PhD¹, Dhaval Patel, MD, FACS^{1,5}, Daoud Meerzaman, PhD³,
Electron Kebebew, MD, FACS^{1,6}

¹Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

²Department of Small Animal Surgery, Royal (Dick) School of Veterinary Studies, The
University of Edinburgh, Edinburgh, UK

³Computational Genomics and Bioinformatics Group, Center for Biomedical Informatics and
Information Technology, National Cancer Institute, Rockville, MD, USA

⁴Neuroendocrine Tumors Service, Endocrine Institute, Sheba Medical Center, and Sackler
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

⁵Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA

⁶Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, CA, USA

*Presented at the 40th Annual Meeting of the American Association of Endocrine Surgeons, Los
Angeles, CA, USA, April 7-9, 2019

Corresponding author

Floryne O. Buishand, DVM, PhD, MRCVS

The Royal (Dick) School of Veterinary Studies and The Roslin Institute

Easter Bush Campus, Midlothian, EH25 9RG

United Kingdom

Ph: + 44 131 650 6079

E: Floryne.Buishand@ed.ac.uk

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

|

Abstract

Background: Adrenocortical carcinoma (ACC) is an aggressive malignancy with a low but variable overall survival rate. The role of long, noncoding RNAs (lncRNAs) in ACC is poorly understood. Thus, in this study we performed lncRNA expression profiling in ACCs, adrenocortical adenomas (ACA), and normal adrenal cortex (NAC).

Methods: lncRNA expression profile, using ArrayStar Human lncRNA/mRNA Expression Microarray V3.0, was analyzed in samples from 11 ACA, 9 ACC, and 5 NAC ~~samples~~. Differentially expressed lncRNAs were validated using TaqMan, real-time quantitative PCR with additional samples. The dataset from the ACC Cancer Genome Atlas (TCGA) project ~~dataset~~ was used to evaluate the prognostic utility of lncRNAs.

Results: Unsupervised hierarchical clustering showed distinct clustering of ACC samples compared with NAC and ACA samples by lncRNA expression profiles. A total of 874 lncRNAs were differentially expressed between ACC and NAC. *LINC00271* expression level was associated with prognosis, patients with low *LINC00271* expression survived a significantly shorter time ~~time~~ than patients with high *LINC00271* expression. Low *LINC00271* expression was positively associated with WNT signaling, cell cycle, and chromosome segregation pathways.

Conclusions: ACC has a distinct lncRNA expression profile. *LINC00271* is downregulated in ACC and appears to be ~~is~~ involved in biological pathways commonly dysregulated in ACC.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

|

Introduction

Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with an annual incidence of 0.7–2.0 cases per million people and a five-year overall survival rate ranging from 32% to 47%).^{1,2} Furthermore, even after complete tumor resection, over half of the patients develop recurrent disease.³ Patients with locally advanced and metastatic ACC often undergo therapy ~~with, which consists of~~ a regimen, including adrenolytic mitotane plus combination chemotherapy with etoposide, doxorubicin, and cisplatin. Unfortunately, this regimen has very limited therapeutic benefit.⁴ The role of adjuvant therapy for ACC is controversial because of questionable therapeutic benefit of current agents and the heterogenous prognosis.³ Understanding the mechanism behind ~~the ACC~~ initiation and progression ~~of ACC~~ could help in identifying diagnostic and prognostic markers, and therapeutic targets.

Several genomic studies of ACC have reported ~~an~~ distinct, ACC genome-wide gene expression ~~and alteration profiles of~~ micro-RNA expression, methylation, and copy number ~~alteration profiles~~ compared with adrenal cortical adenomas (ACAs) and normal adrenal cortex (NAC).⁵⁻¹⁰ These studies have led to the molecular classification of ACC that is relevant for predicting prognosis. Recently, long, noncoding RNAs (lncRNAs) have been suggested to be dysregulated in ACC.¹¹ LncRNAs are RNA transcripts longer than 200 nucleotides that do not encode protein and are localized in the cell nucleus or cytoplasm.¹² The expression of lncRNAs is more tissue-specific than protein-coding genes, and they function as decoys, scaffolds, and enhancer RNAs and are involved in chromatin remodeling, as well as transcriptional and post-transcriptional regulation.¹³

To our knowledge, the study by Glover and colleagues has been the only study that has investigated lncRNA expression profile in ACCs, ACAs, and NAC.¹¹ ~~These investigators~~ reported that the ~~great~~ highest number of differentially expressed lncRNAs were between ACAs

1
2
3
4 and NAC, with almost 3-fold less lncRNAs being differentially expressed between ACCs and
5
6 NAC. This finding suggested that changes in lncRNA expression could be an early event in the
7
8 pathogenesis of both ACC and ACAs. ~~However, t~~This finding, however, is in contrast to the
9
10 results of previous, genome-wide analysis ~~esis results~~ that demonstrated a multistep progression in
11
12 ACC, with increasing genomic changes from NAC to ACA to ACC.⁸ Therefore, to further our
13
14 knowledge of the role of lncRNA in ACCs, we performed lncRNA expression profiling using
15
16 lncRNA microarrays to identify differentially expressed lncRNAs in ACCs compared with NACs
17
18 and ACAs. We also investigated whether lncRNA expression levels were associated with ~~ACC~~
19
20 overall survival times ~~-~~ of ACCs.
21
22
23
24
25
26
27

28 **Materials and methods**

29 *Tissue samples*

30
31
32
33 Patients² tumor tissues were procured after informed consent for genetic studies on a
34
35 procurement clinical protocol proved by our # Institutional Review Board ~~approved~~
36
37 ~~procurement clinical protocol~~ (NCT01005654 and NCT01348698). The tissues were immediately
38
39 snap frozen in liquid nitrogen and stored at -80°C. For this study, we used 11 ACA samples and
40
41 nine ACC samples. Five normal NACs were obtained at the time of organ donation harvesting.
42
43 These 25 tissue samples were used for lncRNA microarray profiling. In addition to these
44
45 samples, an additional 10 ACC samples were included in the quantitative RT-PCR (qRT-PCR)
46
47 validation (Table 1). Tumors were classified as benign when the Weiss criteria scores were less
48
49 than 3 (all the benign samples included had a Weiss score of 0), and tumors were classified as
50
51 ACC₂ when the Weiss criteria scores were more than or equal to 3.¹⁴ Only samples with at least
52
53 80% tumor cells were included for analysis.
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 *RNA extraction*
5

6
7 Total RNA was extracted from fresh frozen tissue samples using an RNeasy Mini Kit
8
9 (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. RNA quality was
10
11 assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Englewood, CO, USA).
12
13
14 Only samples with a minimum RNA integrity number of seven were included for analysis.
15
16
17

18
19 *Microarray profiling*
20

21 The ArrayStar Human LncRNA/mRNA Expression Microarray Version 3.0 (ArrayStar,
22
23 Inc., Rockville, MD, USA) ~~was used for lncRNA profiling, which~~ includes 30,586 lncRNA
24
25 probes and 26,109 coding transcripts, ~~for lncRNA profiling~~. RNA labeling, microarray
26
27 hybridization, slide washing, and scanning were performed based on the standard protocols of the
28
29 ArrayStar. Agilent Feature Extraction software (version 11.0.1.1) which was used to analyze
30
31 acquired array images. The microarray specifications and derived data are accessible through
32
33 National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO)
34
35 accession number GSE124531.
36
37
38
39
40
41
42

43 *TaqMan real-time quantitative PCR*
44

45 RNA was reverse transcribed using the High Capacity₂ cDNA Reverse Transcription kit
46
47 (Applied Biosystems, Foster City, CA, USA). TaqMan qRT-PCR was performed using the
48
49 7900HT₂ fast₂ real-time PCR systems (Applied Biosystems). The reaction contained cDNA,
50
51 TaqMan 2×universal PCR master mix₂, and TaqMan gene expression assays primers (Applied
52
53 Biosystems). LncRNAs were selected for validation based on three criteria: 1) availability of
54
55 validated TaqMan gene expression primer/probe assays, 2) possible role in cancer, and 3)
56
57 magnitude of differential expression. The gene expression assays used were: *HOTTIP*
58
59
60
61
62
63
64
65

1
2
3
4 (Hs03649396_m1), *CHL1* (Hs04332026_m1), *HOXA11-AS1* (Hs_03454334_g1), *CRNDE*
5
6 (HS04404483_m1), *LINC00271* (Hs03657384_m1), *FAM211A-AS1* (Hs03678558_g1), *TBXAS1*
7
8 (Hs01096058_s1) and *GAPDH* (Hs99999905_m1).
9

10 11 12 13 14 *Comparative genomic hybridization (CGH) array analysis*

15
16 We used our previously published, genome-wide, CGH array data in a cohort of NAC,
17
18 ACA, and ACC.⁸ The *LINC100271* site was scanned manually ~~scanned~~ for its copy number
19
20 status using Nexus software.
21
22

23 24 25 26 *Statistical and data analysis*

27
28 LncRNA expression profiles of ACC samples were compared with NAC and ACA
29
30 samples. The Gaussian linear model was used to calculate *P*-values, and false discovery rates
31
32 (FDRs) were calculated using the Benjamini-Hochberg method for each lncRNA. LncRNAs with
33
34 a log₂ fold change ≥ 2 and an FDR < 0.05 were defined as differentially expressed lncRNAs.
35
36 Differentially expressed lncRNAs were mapped to their associated gene names, and then a gene
37
38 set enrichment analysis (GSEA) was performed on these genes. An in-house, R package,
39
40 OmicPath (v 0.1) was used to perform the GSEA to discover potential KEGG pathway
41
42 associations for each set of differentially expressed lncRNAs. Pathways with a *P*-value < 0.05
43
44 were considered statistically significant. Survival curves were plotted using the Kaplan-Meier
45
46 methods, and differences in survival rates were determined using the log-rank test. These
47
48 statistical analyses were done with GraphPad Software with and $P < 0.05$ ~~was~~ considered
49
50 statistically significant.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 The ACC cohort from the [project database of the](https://tcga-data.nci.nih.gov/tcga/) Cancer Genome Atlas (TCGA) ~~project~~
5 ~~database~~ (<https://tcga-data.nci.nih.gov/tcga/>) which included 79 patients with *HOTTIP*, *CHL1*,
6
7
8
9 *HOXA11-AS1*, *CRNDE*, *LINC00271*, *FAM211A-AS1* and *TBXAS1* expression data, as well as
10
11 follow-up information, were used to study the prognostic ~~importancesignificance~~ of lncRNAs.
12
13 For ~~the~~ overall survival analysis, two groups were defined based on the lncRNA expression
14
15 levels in the primary tumor. Those with a lncRNA level ranked in the top half were classified into
16
17 the high expression group and the rest into the low expression group based on the median value.
18
19
20

21 The gene expression profiles of ACC samples deposited in the TCGA project database
22
23 were analyzed to compare expression patterns in tumors with high ($n = 39$) vs. low *LINC100271*
24
25 expression ($n = 40$). The downloaded data consisted of quantified gene expression data, that were
26
27 further processed using the DESeq2 package.¹⁵ The differentially expressed genes were annotated,
28
29 and GSEA analysis was performed using the clusterProfiler package.¹⁶
30
31
32
33
34
35

36 Results

37 Differentially expressed lncRNAs in ACC versus NAC

38
39
40
41 Unsupervised hierarchical and heat map clustering showed distinct clustering of ACC
42
43 samples compared with NAC and ACA samples (Fig. 1). ~~In these samples, 874 Eight hundred~~
44
45 ~~and seventy-four~~ lncRNAs were differentially expressed in ACC compared with NAC, of which
46
47 409 were upregulated, and 465 were downregulated. The 874 differentially expressed lncRNAs
48
49 corresponded to 330 annotated lncRNA genes. Among the upregulated lncRNAs, the ~~greathighest~~
50
51 log2 fold change was 8.5 for an unannotated lncRNA gene, and *RAD50* was the ~~gerathighest~~
52
53 upregulated, annotated lncRNA gene with a log2 fold change of 6.1. Among the downregulated
54
55 lncRNAs, the ~~greathighest~~ log2 fold change was 8.3 for an unannotated lncRNA gene and 6.4 for
56
57 *HAND2*, the ~~greathighest~~ downregulated annotated lncRNA gene; ~~of these, 183. One hundred and~~
58
59
60
61
62
63
64
65

1
2
3
4 ~~eighty-three~~ differently expressed lncRNAs had established functions in cancer development and
5
6 cancer progression. Selected carcinogenesis-related lncRNAs are summarized in Table 2.
7
8

9 To test the validity of the microarray findings, seven lncRNAs (*HOTTIP*, *CHLI*,
10 *HOXA11-AS1*, *CRNDE*, *LINC00271*, *FAM211A-AS1* and *TBXAS1*) were selected among the
11 carcinogenesis-related, differentially expressed lncRNAs, and their expression was analyzed by
12 TaqMan qRT-PCR. The validation cohort included 19 ACC samples and 5 NAC samples.
13
14 *HOTTIP*, *HOXA11-AS1* and *CRNDE* were overexpressed in ACC ($P < 0.05$) and confirmed by
15 TaqMan qRT-PCR in the validation cohort ($P < 0.05$; Fig. 2). Expression of *LINC00271*,
16 *FAM211A-AS1* and *TBXAS1* expression was downregulated in ACC ($P < 0.05$) and also by
17 TaqMan qRT-PCR ($P < 0.05$) (Fig 2). The microarray result for *CHLI* was not confirmed in the
18 validation cohort. Upregulated expression of *CHLI* was identified in the microarray analysis ($P <$
19 0.05) while *CHLI* was found not to be ~~not-significantly~~ upregulated by TaqMan qRT-PCR in the
20 validation cohort.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 *Differentially expressed lncRNAs in ACC versus ACA*

39
40 When comparing ACC with ACA, 1076 ~~One thousand seventy-six~~ lncRNAs were
41 differentially expressed ~~in ACC compared with ACA~~, of which 780 were upregulated, and 296
42 were downregulated. The 1,076, differentially expressed lncRNAs corresponded to 376 annotated
43 lncRNA genes. Among the upregulated lncRNAs, the greathighest log2 fold change was 8.2 for
44 an unannotated lncRNA and 7.0 for *NKAIN4*, the greathighest upregulated annotated lncRNA.
45
46 Among the downregulated lncRNAs, the greathighest log2 fold change was 7.1 for an
47 unannotated lncRNA gene and 6.9 for *SSTR5*, the greathighest downregulated annotated lncRNA.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 There was overlap in 206 lncRNAs as they were downregulated in ACC compared to
5
6 NAC and in ACC compared to ACA, and 355 lncRNAs overlapped as they were upregulated in
7
8 ACC compared to NAC and ACA (Fig. 3).
9

10 11 12 13 14 *Differentially expressed lncRNAs in ACA versus NAC*

15
16 Unsupervised hierarchical and heat map clustering showed that NAC samples clustered
17
18 together with ACA samples (Fig. 1). Only 10-ten lncRNAs were differentially expressed in ACA
19
20 compared with NAC.
21
22

23 24 25 26 *Functional pathway analysis*

27
28 KEGG pathway analysis of the differentially expressed and annotated lncRNAs in ACC
29
30 compared with NAC and in ACC compared with ACA was performed to understand the
31
32 biological relevance of these lncRNAs. Twenty-one pathways were significantly enriched in
33
34 ACC versus ACA and 29 pathways were significantly enriched in ACC versus NAC (Tables 3
35
36 and 4). Twelve of the altered 21 pathways were common to the comparison of ACC versus ACA
37
38 and ACC versus NAC. The KEGG pathways common to both comparisons included
39
40 ‘Transcriptional misregulation in cancer’ and ‘ECM-receptor interaction’.
41
42
43
44
45
46
47

48 49 *Prognostic lncRNAs in ACC*

50
51 Using the survival data of the ACC TCGA cohort, the prognostic significance of
52
53 *HOTTIP*, *HOXA11-AS1*, *CRNDE*, *LINC00271*, *FAM211A-AS1* and *TBXAS1* was analyzed. Only
54
55 *LINC00271* expression (Fig. 4A) was found to be associated with prognosis. *LINC00271*
56
57 expression levels were positively associated with survival time (Fig. 4B). Median survival time
58
59 for the low-*LINC00271* expression group ($n = 40$) was 4.9 years, whereas it was not reached for
60
61
62
63
64
65

1
2
3
4 the high-*LINC00271* expression group ($n = 39$) ($P < 0.019$) (Fig 4C). Student's t-tests
5
6 demonstrated that *LINC00271* expression levels of stage I tumors were ~~greatly~~ significantly higher
7
8 than those of stage IV tumors ($P < 0.006$).
9

10 11 12 13 14 *Identification of LINC00271-associated biological pathways by Gene Set Enrichment Analysis*

15
16 To identify *LINC00271*-associated biological pathways, GSEA was performed using high
17
18 throughput RNA-sequencing data from the TCGA ACC cohort. Among the GO gene sets, the
19
20 WNT signaling pathway, cell cycle, chromosome segregation, and tissue morphogenesis were
21
22 found to be ~~statistically~~ significantly associated with low *LINC00271* expression in the ACC
23
24 TCGA cohort (Fig. 5), suggesting that *LINC00271* may be involved in ACC development and/or
25
26 progression through the above cancer-associated signaling pathways.
27
28
29
30
31
32

33 34 *LINC00271 copy number alterations*

35
36 We performed a analysis of the *LINC00271* chromosomal locus, 6q23.3, using
37
38 genome-wide CGH array data that were ~~previously~~ generated previously in a cohort of NAC,
39
40 ACA, and ACC¹⁰, ~~was performed~~ to examine whether the *LINC00271* site demonstrated any
41
42 copy number alterations to explain its downregulated expression in ACC. One ~~out~~ of 11 NAC
43
44 samples demonstrated a deletion at 6q23.3, whereas 2 of 18 ACA samples demonstrated deletions
45
46 at 6q23.3, and two other ACA samples demonstrated amplifications at 6q23.3. The *LINC00271*
47
48 locus appeared to be the ~~was~~ most unstable in ACCs, with 4 of 19 ACC samples demonstrating
49
50 deletions, and 4 of 19 ACC samples demonstrating amplifications of 6q23.3.
51
52
53
54
55
56

57 58 **Discussion**

59
60 This study demonstrated that NAC, ACA, and ACC have distinct lncRNA expression
61
62
63
64
65

1
2
3
4 profiles, and that *LINC00271*, 2whhich appeared to be involved in biological pathways
5 commonly dysregulated in ACC, may beis a prognostic marker in ACC.
6
7

8
9 When compared with NAC, 874 Eight hundred and seventy four lncRNAs were
10 differentially expressed in ACC, compared with NAC, 1076 lncRNAs were differentially
11 expressed in ACA compared with ACC, and only t10en lncRNAs were differentially expressed in
12 ACA vs. NAC. Previously, Glover and colleagues demonstrated that the greathighest number of
13 differentially expressed lncRNAs in their study wasere between ACA and NAC (2655 lncRNAs),
14 while 956 lncRNAs were differentially expressed between ACC and NAC, and 85 lncRNAs were
15 differentially expressed between ACC and ACA.¹¹ The data of these investiagotrs y suggested
16 that changes in lncRNA expression could be an early part in the pathogenesis of both ACC and
17 ACAs. In contrast, However, our results are not entirely consistent with their findings, because as
18 we found only 10ten lncRNAs that were differentially expressed between ACA and NAC.;
19 However, this finding is in line with the multistep hypothesis in tumorigenesis that is present in
20 most human cancers - progressive genetic/genomic alterations increasing/accumulating from
21 NAC to ACA to ACC as previously-described previously in our integrated, genome-wide gene
22 expression, gene methylation, microRNA expression, and CGH analysis in human samples form
23 NACs, ACAs, and ACCs samples.⁸ The multistep progression from NAC to ACA to ACC is
24 further supported by our finding of 296 lncRNAs differentially expressed between ACA versus
25 ACC and 465 lncRNAs differentially expressed between ACC vs. NAC. Overall, we found less
26 differently expressed lncRNAs in adrenocortical neoplasmstumors compared to the Glover et al.
27 study¹¹, but we used a more stringent cut-off in fold-change cut-off to identify differentially
28 expressed lncRNAs, and the NAC samples used in our study were not adjacent normal tissue to
29 ACAs.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

59
60 In the current study, the TCGA ACC dataset was used to screen for prognostic
61
62
63
64
65

1
2
3
4 significance of differentially expressed lncRNAs. *LINC00271* was found to be associated with
5
6 malignancy; ~~with~~ patients with low *LINC00271* expression levels survived ~~ed~~ a significantly
7
8 ~~less~~ shorter time than patients with high *LINC00271* expression levels. Previously, ~~a~~
9
10 ~~statistically significantly~~ lower expression of *LINC00271* has been described in invasive
11
12 breast carcinoma, lung adenocarcinoma, kidney renal papillary cell carcinoma, head and neck
13
14 squamous cell carcinoma, and papillary thyroid cancer.¹⁷ In addition, *LINC00271* has been found
15
16 to be an independent risk factor for extrathyroidal extension, lymph node metastasis, advanced
17
18 tumor stage III/IV, and recurrence in papillary thyroid cancer.¹⁷ GSEA revealed that genes
19
20 associated with cell adhesion molecules, ~~the~~ TP53 signaling pathway, ~~the~~ JAK/STAT signaling
21
22 pathway, and ~~the~~ cell cycle were ~~statistically significantly~~ enriched in papillary thyroid cancer
23
24 with a low *LINC00271* expression versus papillary thyroid cancer with ~~great~~ higher *LINC00271*
25
26 expression. We also found that genes associated with cell cycle were associated with low
27
28 *LINC00271* expression in the TCGA ACC cohort. Further *LINC00271* expression was positively
29
30 associated with ~~the~~ WNT signaling pathway and chromosome segregation ~~which are~~; biological
31
32 pathways commonly dysregulated in ACC.^{18,19} Thus, our findings and other investigators studies
33
34 suggest that *LINC00271* could contribute to abnormal activation of these pathways in a tumor
35
36 suppressor manner, however, further mechanistic studies are needed to test this hypothesis.
37
38
39
40
41
42
43
44

45
46 Studies have suggested that genes with causal roles in tumorigenesis are often located in
47
48 chromosomal areas with ~~alterations in~~ copy number ~~alterations~~.^{20,21} Gene expression levels are
49
50 directly dependent on chromosomal aneuploidies in carcinomas.²² The strongest correlations have
51
52 been found between genomic copy number and average, chromosome-wide expression levels, but
53
54 the expression of individual genes has also been associated with genomic copy numbers.²³
55
56
57
58 LncRNAs expression levels have been positively correlated with ~~alterations in~~ copy number
59
60 ~~alterations~~ as well.^{24,25} Therefore, we investigated whether ~~alterations in~~ copy number ~~alterations~~
61
62
63
64
65

1
2
3
4 | were present at the *LINC00271* chromosomal locus, 6q23.3. This region had the ~~great~~highest
5
6 alteration in ACC samples with 21% of samples demonstrating amplifications and another 21%
7
8 demonstrating deletions, while only 11% of ACA samples had amplifications and another 11%
9
10 deletions of 6q23.3. The instability of 6q23.3 might explain the dysregulated expression of
11
12 *LINC00271* in ACC.
13
14

15
16 In conclusion, ACC has a distinct lncRNA expression profile, and *LINC00271*
17
18 downregulation is ~~appears to be~~ associated with malignancy and ~~may be~~is involved in biological
19
20 pathways commonly dysregulated in ACC.
21
22
23
24
25

26 **Disclosure of interest**

27
28 The authors report no proprietary or commercial interest in any product mentioned or concept
29
30 discussed in this article.
31
32
33
34
35

36 **Acknowledgements**

37
38 This work was supported by the intramural research program of the Center for Cancer Research,
39
40 National Cancer Institute, National Institutes of Health (1ZIABC011275-09).
41
42
43
44

45 **References**

- 46
47
48
49
50
51 1. Bilmoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, et al.
52 Adrenocortical carcinoma in the United States: treatment utilization and prognostic
53 factors. *Cancer* 2008;113:3130-6.
54
55
56
57 2. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, et
58
59 al. Adrenocortical carcinoma: a population-based study on incidence and survival in the
60
61
62
63
64
65

- 1
2
3
4 Netherlands since 1993. *Eur J Cancer* 2013;49:2579-86.
5
6
7 3. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, et al. Recurrence of
8
9 adrenal cortical carcinoma following resection: surgery alone can achieve results equal to
10
11 surgery plus mitotane. *Ann Surg Oncol* 2010;17:263-70.
12
13
14 4. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination
15
16 chemotherapy in advanced adrenocortical carcinoma. *N Engl J Med* 2012;366:2189-97.
17
18
19 5. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, et al. Molecular
20
21 classification and prognostication of adrenocortical tumors by transcriptome profiling.
22
23 *Clin Cancer Res* 2009;15:668-76.
24
25
26 6. Soon PS, Gill AJ, Benn DE, Clarkson A, Robinson BG, McDonald KL, et al. Microarray
27
28 gene expression and immunohistochemistry analyses of adrenocortical tumors identify
29
30 IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. *Endocr Relat*
31
32 *Cancer* 2009;16:573-83.
33
34
35
36 7. Rechache NS, Wang Y, Stevenson HS, Killian JK, Edelman DC, Merino M, et al. DNA
37
38 methylation profiling identifies global methylation differences and markers of
39
40 adrenocortical tumors. *J Clin Endocrinol Metab* 2012;97:E1004-13.
41
42
43 8. Gara SK, Wang Y, Patel D, Liu-Chittenden Y, Jain M, Boufraquech M, et al. Integrated
44
45 genome-wide analysis of genomic changes and gene regulation in human adrenocortical
46
47 tissue samples. *Nucleic Acids Res* 2015;43:9327-39.
48
49
50
51 9. Assie G, Letouze E, Fassnacht M, Jouinot A, Luscip W, Barreau O., et al. Integrated
52
53 genomic characterization of adrenocortical carcinoma. *Nat Genet* 2014;46:607-12.
54
55
56 10. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al.
57
58 Comprehensive pan-genomic characterization of adrenocortical carcinoma. *Cancer Cell*
59
60 2016;29:723-36.
61
62
63
64
65

- 1
2
3
4 11. Glover AR, Zhao JT, Ip JC, Lee JC, Robinson BG, Gill AJ, et al. Long noncoding RNA
5 profiles of adrenocortical cancer can be used to predict recurrence. *Endocr Relat Cancer*
6 2015;22:99-109.
7
8
- 9
10
11 12. Li L, Chang HY. Physiological roles of long noncoding RNAs: insight from knockout
12 mice. *Trends Cell Biol* 2014;24:594-602.
13
14
- 15
16 13. Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in
17 cancer. *Genomics Proteomics Bioinformatics* 2016;14:42-54.
18
19
- 20
21 14. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in
22 adrenocortical carcinoma. *Am J Surg Pathol* 1989;13:202-6.
23
24
- 25
26 15. Love M, Huber W, Anders S. Moderated estimation of fold change and dispersion for
27 RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.
28
29
- 30
31 16. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological
32 themes among gene clusters. *OMICS* 2012;16:284-7.
33
34
- 35
36 17. Ma B, Liao T, Wen D, Dong C, Zhou L, Yang S, et al. Long intergenic non-coding RNA
37 271 is predictive of a poorer prognosis of papillary thyroid cancer. *Sci Rep* 2016;6:36973.
38
39
- 40
41 18. Roshani L, Fujioka K, Auer G, Kjellman M, Lagercrantz S, Larsson C. Aberrations of
42 centrosomes in adrenocortical tumors. *Int J Oncol* 2002;20:1161-5.
43
44
- 45
46 19. Ragazzon B, Libe R, Gaujoux S, Assie G, Fratticci A, Launay P, et al. Transcriptome
47 analysis reveals that p53 and b-catenin alterations occur in a group of aggressive
48 adrenocortical cancers. *Cancer Res* 2010;70:8276-8281.
49
50
- 51
52 20. Kim TM, Xi R, Luquette LJ, Park RW, Johnson MD, Park PJ. Functional genomic
53 analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. *Genome*
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

21. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, et al. Pan-cancer patterns of somatic copy number alteration. *Nat Genet* 2013;45:1134-40.

22. Grade M, Hormann P, Becker S, Hummon AB, Wangsa D, Varma S, et al. Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. *Cancer Res.* 2007;67:41-56.

23. Ried T, Hu Y, Difilippantonio MJ, Ghadimi BM, Grade M, Camps J. The consequences of chromosomal aneuploidy on the transcriptome of cancer cells. *Biochim Biophys Acta* 2012;1819:784-93.

24. Chen H, Xu J, Hong J, Tang R, Zhang X, Fang JY. Long noncoding RNA profiles identify five distinct molecular subtypes of colorectal cancer with clinical relevance. *Mol Oncol* 2014;8:1393-403.

25. Deng Y, Luo S, Zhang X, Zou C, Yuan H, Liao G, et al. A pan-cancer atlas of cancer hallmark-associated candidate driver lncRNAs. *Mol Oncol* 2018;12:1980-2005.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Tables

Table 1. Clinical features of ACA and ACC patients

	ACA*	ACC† included in microarray	ACC in validation cohort
Number of patients	11	9	10
Age (average ± SD)	46.0 years ± 198.7	52.2 years ± 154.7	46.7 years ± 143.7
Sex (female/male)	9/2	7/2	6/4
Tumor size (average ± SD)	3.8 cm ± 1.8	6.7 cm ± 5.9	5.4 cm ± 2.2
Functional Syndrome‡	55%	44%	30%
Adrenal hypercortisolism	3	4	3
Primary hyperaldosteronism	3	1	0
Nonfunctioning	6	4	7

* ACA, adrenocortical adenoma

† ACC, adrenocortical carcinoma

‡ Functional status at initial presentation

Table 2. Selected carcinogenesis-related differentially expressed lncRNAs between ACC and NAC

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Sequence name	Gene symbol	Regulation	P-value	Log2 fold change	Chromosome	Relationship
ENST00000534886	<i>SRRM4</i>	Up	0.001	5.14	Chr12	Intron sense-overlapping
ENST00000472494	<i>HOTTIP</i>	Up	9.11 x 10 ⁻⁵	5.05	Chr7	Bidirectional
ENST00000514846	<i>GRK6</i>	Up	9.92 x 10 ⁻⁶	4.75	Chr5	Natural antisense
NR_002795	<i>HOXA11</i>	Up	4.61 x 10 ⁻⁵	4.05	Chr7	Bidirectional
NR_045572	<i>CHL1</i>	Up	3.45 x 10 ⁻⁴	4.16	Chr3	Exon sense-overlapping
ENST00000558031	<i>CRNDE</i>	Up	1.30 x 10 ⁻⁵	2.45	Chr16	Intergenic
ENST00000502941	<i>HAND2</i>	Down	1.52 x 10 ⁻⁷	6.35	Chr4	Bidirectional
ENST00000450445	<i>BNC2</i>	Down	1.36 x 10 ⁻⁶	5.01	Chr9	Intronic antisense
ENST00000417354	<i>DNM3</i>	Down	4.46 x 10 ⁻⁶	3.50	Chr1	Intronic antisense
NR_029394	<i>TBXAS1</i>	Down	2.15 x 10 ⁻⁴	2.51	Chr7	Exon sense-overlapping
NR_026805	<i>LINC00271</i>	Down	3.99 x 10 ⁻⁶	2.50	Chr6	Bidirectional
NR_027158.1	<i>FAM211A-AS1</i>	Down	2.96 x 10 ⁻³	2.06	Chr17	Intronic antisense

Table 3. Statistically significant different KEGG pathways in ACC versus ACA

Pathways	Genes	P-value
Pathways in cancer	<i>ADCY2, RALBP1, CSF2RA, DAPK1, FGF13, GSK3B, BIRC5, ITGA3, MMP9, PTGER3, SLC2A1, TGFB2, PAX8, RUNX1</i>	1.791e-3
Vascular smooth muscle contraction	<i>KCNMB2, ADCY2, KCNMA1, AVPRIA, PRKCQ, PRKG1</i>	3.251e-3
Glucagon signaling pathway	<i>ADCY2, PRKAG2, PGAM2, PHKA2, SLC2A1</i>	5.823e-3
Malaria	<i>ITGAL, TGFB2, THBS4</i>	7.960e-3
Transcriptional misregulation in cancer	<i>HOXA10, HOXA11, MMP9, PAX8, HMGA2, HIST1H3G, RUNX1</i>	8.716e-3
Insulin secretion	<i>KCNMB2, ADCY2, KCNMA1, SLC2A1</i>	1.209e-2
Circadian rhythm	<i>ADCY2, PRKG1, PTGER3</i>	1.266 e-2
Salivary secretion	<i>NPAS2, PRKAG2</i>	1.346 e-2
Cell cycle	<i>ADCY2, KCNMA1, LYZ, PRKG1</i>	1.455 e-2
Colorectal cancer	<i>E2F5, GSK3B, MAD2L1, RBL2, TGFB2</i>	1.522 e-2
FoxO signaling pathway	<i>GSK3B, BIRC5, TGFB2</i>	1.786 e-2
Glycolysis / Gluconeogenesis	<i>S1PR1, PRKAG2, RBL2, BNIP3, TGFB2</i>	2.149 e-2
Ubiquitin mediated proteolysis	<i>PGAM2, ADPGK, FBP2</i>	2.307 e-2
Adipocytokine signaling pathway	<i>UBE2S, UBE2D4, SIAH1, UBE2G2, ITCH</i>	2.367 e-2
Signaling pathways regulating pluripotency of stem cells	<i>PRKAG2, PRKCQ, SLC2A1</i>	2.661 e-2
Bladder cancer	<i>ESRRB, GSK3B, PAX6, POU5F1B, PCGF1</i>	2.762 e-2
Insulin resistance	<i>DAPK1, MMP9</i>	2.841 e-2
RNA degradation	<i>GSK3B, PRKAG2, PRKCQ, SLC2A1</i>	3.180 e-2
ECM-receptor interaction	<i>LSM1, EXOSC10, BTG1</i>	3.605 e-2
Hypertrophic cardiomyopathy (HCM)	<i>SV2C, ITGA3, THBS4</i>	4.385e-2

Note Pathways common to the comparison of ACC versus ACA and ACC versus NAC are written in bold type

Table 4. Statistically significantly different KEGG pathways in ACC versus NAC

Pathways	Genes	P-value
ECM-receptor interaction	<i>COL6A2, SV2C, ITGA3, ITGA9, THBS2</i>	5.329e-4
Circadian rhythm	<i>NPAS2, PRKAG2, BHLHE40</i>	5.596e-4
Vascular smooth muscle contraction	<i>MRVII, KCNMA1, AVPR1A, PRKACB, PRKCQ, PRKG1</i>	7.222e-4
Adipocytokine signaling pathway	<i>IKBKB, PRKAG2, PRKCQ, SLC2A1</i>	1.759e-3
Transcriptional misregulation in cancer	<i>HOXA11, MEIS1, MMP9, UTY, PAX8, HMGA2, HIST1H3G</i>	1.785e-3
Cocaine addiction	<i>GRIN3B, GRM3, PRKACB</i>	3.175e-3
Salivary secretion	<i>KCNMA1, LYZ, PRKACB, PRKG1</i>	5.0121e-3
Glucagon signaling pathway	<i>PRKAG2, PGAM2, PRKACB, SLC2A1</i>	8.511e-3
Glycolysis / Gluconeogenesis	<i>ADH1A, PGAM2, ADPGK</i>	9.687e-3
Insulin resistance	<i>IKBKB, PRKAG2, PRKCQ, SLC2A1</i>	1.161e-2
Nicotine addiction	<i>CHRNA4, GRIN3B</i>	1.345e-2
Proteasome	<i>PSMA3, PSMD7</i>	1.740e-2
Platelet activation	<i>LYN, PRKACB, PRKG1, TBXAS1</i>	1.817e-2
Hypertrophic cardiomyopathy (HCM)	<i>ITGA3, ITGA9, PRKAG2</i>	1.998e-2
Hedgehog signaling pathway	<i>CDON, PRKACB</i>	2.074e-2
Endocrine and other factor-regulated calcium reabsorption	<i>DNM3, PRKACB</i>	2.074e-2
Insulin secretion	<i>KCNMA1, PRKACB, SLC2A1</i>	2.161e-2
Neuroactive ligand-receptor interaction	<i>CHRNA4, GRIN3B, GRM3, AVPR1A, RXFP1, SSTR5, THRB</i>	2.227e-2
Dilated cardiomyopathy	<i>ITGA3, ITGA9, PRKACB</i>	2.602e-2
Morphine addiction	<i>GRK6, PDE4D, PRKACB</i>	2.697e-2
NF-kappa B signaling pathway	<i>IKBKB, LYN, PRKCQ</i>	2.891e-2
Circadian entrainment	<i>PRKACB, PRKG1, CACNA1H</i>	3.094e-2
Regulation of lipolysis in adipocytes	<i>PRKACB, PRKG1</i>	3.273e-2
Long-term depression	<i>LYN, PRKG1</i>	3.900e-2
Focal adhesion	<i>COL6A2, ITGA3, ITGA9, PAK3, THBS2</i>	4.064e-2
T cell receptor signaling pathway	<i>IKBKB, PAK3, PRKCQ</i>	4.110e-2
Longevity regulating pathway – multiple species	<i>PRKAG2, PRKACB</i>	4.584e-2
Renin secretion	<i>KCNMA1, PRKACB</i>	4.584e-2
Renal cell carcinoma	<i>PAK3, SLC2A1</i>	4.946e-2

Note Pathways common to the comparison of ACC versus ACA and ACC versus NAC are written in bold type

1
2
3
4 **Figure legends**
5
6
7
8

9 **Fig 1.** Unsupervised hierarchical clustering and heat map of lncRNA expression between
10 adrenocortical carcinoma (ACC), adrenocortical adenoma (ACA), and normal adrenal cortex
11 (NAC). Each column represents a sample, and each row represents a lncRNA. High relative
12 expression is indicated in yellow and low relative expression in red.
13
14
15
16
17
18
19
20

21 **Fig 2.** TaqMan qRT-PCR validation of lncRNA microarray analysis. Fold-change in comparison
22 of ~~ACC~~adrenocortical carcinoma versus ~~NAC~~normal adrenal cortex, * $P < 0.05$.
23
24
25
26
27

28 **Fig 3.** Venn diagram showing the number of overlapping up- or downregulated lncRNAs in the
29 different comparisons. ~~ACC, adrenocortical carcinoma; ACA, adrenocortical adenoma; NAC,~~
30 ~~normal adrenal cortex.~~
31
32
33
34
35
36
37

38 **Fig 4.** *LINC00271* expression and prognosis. A, Distribution of *LINC00271* expression of ~~ACC~~
39 ~~adrenocortical carcinoma~~ samples from the TCGA dataset. Red points were defined as low-
40 *LINC00271* expression group and black points were defined as high-*LINC00271* expression
41 group. B, *LINC00271* expression is positively correlated to survival time (Pearson correlation
42 coefficient = 0.50). C, Kaplan-Meier plot of overall survival in the TCGA ~~the ACC~~adrenocortical
43 ~~carcinoma~~ cohort is shown according to *LINC00271* expression level (low vs. high).
44
45
46
47
48
49
50
51
52
53
54

55 **Fig 5.** *LINC00271*-associated biological signaling pathways. Based on the TCGA dataset, GSEA
56 showed that genes associated with WNT signaling pathway, cell cycle, chromosome segregation
57 and tissue morphogenesis were ~~statistically ignificantly~~ enriched in lower *LINC00271* versus
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

greahigher *LINC00271* expressing ~~adrenocortical carcinomas~~ACCs. FDR, false discovery rate;
NES, normalized enrichment score.

1
2
3
4 **Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and**
5
6 **LINC00271 is downregulated in malignancy***
7
8
9

10 Floryne O. Buishand, DVM, PhD, MRCVS^{1,2}, Yi Liu-Chittenden, PhD¹, Yu Fan, MS³, Amit
11
12 Tirosh, MD⁴, Sudheer K. Gara, PhD¹, Dhaval Patel, MD, FACS^{1,5}, Daoud Meerzaman, PhD³,
13
14 Electron Kebebew, MD, FACS^{1,6}
15
16
17

18
19 ¹Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

20 ²Department of Small Animal Surgery, Royal (Dick) School of Veterinary Studies, The
21 University of Edinburgh, Edinburgh, UK

22 ³Computational Genomics and Bioinformatics Group, Center for Biomedical Informatics and
23 Information Technology, National Cancer Institute, Rockville, MD, USA

24 ⁴Neuroendocrine Tumors Service, Endocrine Institute, Sheba Medical Center, and Sackler
25 Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

26 ⁵Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA

27 ⁶Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, CA, USA
28
29
30
31

32 *Presented at the 40th Annual Meeting of the American Association of Endocrine Surgeons, Los
33
34 Angeles, CA, USA, April 7-9, 2019
35
36
37
38

39 *Corresponding author*

40
41
42 Floryne O. Buishand, DVM, PhD, MRCVS

43
44 The Royal (Dick) School of Veterinary Studies and The Roslin Institute

45
46 Easter Bush Campus, Midlothian, EH25 9RG

47
48
49 United Kingdom

50
51
52 Ph: + 44 131 650 6079

53
54
55 E: Floryne.Buishand@ed.ac.uk
56
57
58
59
60
61
62
63
64
65

1
2
3
4 **Abstract**
5

6 *Background:* Adrenocortical carcinoma (ACC) is an aggressive malignancy with a low but
7
8 variable overall survival rate. The role of long, noncoding RNAs (lncRNAs) in ACC is poorly
9
10 understood. Thus, in this study we performed lncRNA expression profiling in ACCs,
11
12 adrenocortical adenomas (ACA), and normal adrenal cortex (NAC).
13
14

15
16 *Methods:* LncRNA expression profile using ArrayStar Human LncRNA/mRNA Expression
17
18 Microarray V3.0 was analyzed in samples from 11 ACA, 9 ACC, and 5 NAC. Differentially
19
20 expressed lncRNAs were validated using TaqMan, real-time quantitative PCR with additional
21
22 samples. The dataset from the ACC Cancer Genome Atlas (TCGA) project was used to evaluate
23
24 the prognostic utility of lncRNAs.
25
26

27
28 *Results:* Unsupervised hierarchical clustering showed distinct clustering of ACC samples
29
30 compared with NAC and ACA samples by lncRNA expression profiles. A total of 874 lncRNAs
31
32 were differentially expressed between ACC and NAC. *LINC00271* expression level was
33
34 associated with prognosis, patients with low *LINC00271* expression survived a shorter time than
35
36 patients with high *LINC00271* expression. Low *LINC00271* expression was positively associated
37
38 with WNT signaling, cell cycle, and chromosome segregation pathways.
39
40

41
42 *Conclusions:* ACC has a distinct lncRNA expression profile. *LINC00271* is downregulated in
43
44 ACC and appears to be involved in biologic pathways commonly dysregulated in ACC.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Introduction

Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with an annual incidence of 0.7–2.0 cases per million people and a five-year overall survival rate ranging from 32% to 47%).^{1,2} Furthermore, even after complete tumor resection, over half of the patients develop recurrent disease.³ Patients with locally advanced and metastatic ACC often undergo therapy with a regimen including adrenolytic mitotane plus combination chemotherapy with etoposide, doxorubicin, and cisplatin. Unfortunately, this regimen has very limited therapeutic benefit.⁴ The role of adjuvant therapy for ACC is controversial because of questionable therapeutic benefit of current agents and the heterogenous prognosis.³ Understanding the mechanism behind the initiation and progression of ACC could help in identifying diagnostic and prognostic markers, and therapeutic targets.

Several genomic studies of ACC have reported a distinct, ACC genome-wide gene expression and alteration profiles of micro-RNA expression, methylation, and copy number compared with adrenal cortical adenomas (ACAs) and normal adrenal cortex (NAC).⁵⁻¹⁰ These studies have led to the molecular classification of ACC that is relevant for predicting prognosis. Recently, long, noncoding RNAs (lncRNAs) have been suggested to be dysregulated in ACC.¹¹ LncRNAs are RNA transcripts longer than 200 nucleotides that do not encode protein and are localized in the cell nucleus or cytoplasm.¹² The expression of lncRNAs is more tissue-specific than protein-coding genes, and they function as decoys, scaffolds, and enhancer RNAs and are involved in chromatin remodeling, as well as transcriptional and post-transcriptional regulation.¹³

To our knowledge, the study by Glover and colleagues has been the only study that has investigated lncRNA expression profile in ACCs, ACAs, and NAC.¹¹ These investigators reported that the greatest number of differentially expressed lncRNAs were between ACAs and NAC, with almost 3-fold less lncRNAs being differentially expressed between ACCs and NAC.

1
2
3
4 This finding suggested that changes in lncRNA expression could be an early event in the
5
6 pathogenesis of both ACC and ACAs. This finding, however, is in contrast to the results of
7
8 previous, genome-wide analyses that demonstrated a multistep progression in ACC, with
9
10 increasing genomic changes from NAC to ACA to ACC.⁸ Therefore, to further our knowledge of
11
12 the role of lncRNA in ACCs, we performed lncRNA expression profiling using lncRNA
13
14 microarrays to identify differentially expressed lncRNAs in ACCs compared with NACs and
15
16 ACAs. We also investigated whether lncRNA expression levels were associated with overall
17
18 survival times of ACCs.
19
20
21
22
23
24
25

26 **Materials and methods**

27 *Tissue samples*

28
29 Patient tumor tissues were procured after informed consent for genetic studies on a
30
31 procurement clinical protocol pproved by our Institutional Review Board(NCT01005654 and
32
33 NCT01348698). The tissues were immediately snap frozen in liquid nitrogen and stored at -80°C.
34
35 For this study, we used 11 ACA samples and nine ACC samples. Five normal NACs were
36
37 obtained at the time of organ donation harvesting. These 25 tissue samples were used for lncRNA
38
39 microarray profiling. In addition to these samples, an additional 10 ACC samples were included
40
41 in the quantitative RT-PCR (qRT-PCR) validation (Table 1). Tumors were classified as benign
42
43 when the Weiss criteria scores were less than 3 (all the benign samples included had a Weiss
44
45 score of 0), and tumors were classified as ACC, when the Weiss criteria scores were more than or
46
47 equal to 3.¹⁴ Only samples with at least 80% tumor cells were included for analysis.
48
49
50
51
52
53
54
55
56

57 *RNA extraction*

58
59 Total RNA was extracted from fresh frozen tissue samples using an RNeasy Mini Kit
60
61
62
63
64
65

1
2
3
4 (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. RNA quality was
5
6 assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Englewood, CO, USA).
7
8
9 Only samples with a minimum RNA integrity number of seven were included for analysis.
10

11 12 13 14 *Microarray profiling*

15
16 The ArrayStar Human LncRNA/mRNA Expression Microarray Version 3.0 (ArrayStar,
17
18 Inc., Rockville, MD, USA) used for lncRNA profiling includes 30,586 lncRNA probes and
19
20 26,109 coding transcripts,. RNA labeling, microarray hybridization, slide washing, and scanning
21
22 were performed based on the standard protocols of the ArrayStar. Agilent Feature Extraction
23
24 software (version 11.0.1.1) which was used to analyze acquired array images. The microarray
25
26 specifications and derived data are accessible through National Center for Biotechnology
27
28 Information (NCBI) Gene Expression Omnibus (GEO) accession number GSE124531.
29
30
31
32
33
34
35

36 *TaqMan real-time quantitative PCR*

37
38 RNA was reverse transcribed using the High Capacity, cDNA Reverse Transcription kit
39
40 (Applied Biosystems, Foster City, CA, USA). TaqMan qRT-PCR was performed using the
41
42 7900HT, fast, real-time PCR systems (Applied Biosystems). The reaction contained cDNA,
43
44 TaqMan 2×universal PCR master mix, and TaqMan gene expression assays primers (Applied
45
46 Biosystems). LncRNAs were selected for validation based on three criteria: 1) availability of
47
48 validated TaqMan gene expression primer/probe assays, 2) possible role in cancer, and 3)
49
50 magnitude of differential expression. The gene expression assays used were: *HOTTIP*
51
52 (Hs03649396_m1), *CHL1* (Hs04332026_m1), *HOXA11-AS1* (Hs_03454334_g1), *CRNDE*
53
54 (HS04404483_m1), *LINC00271* (Hs03657384_m1), *FAM211A-AS1* (Hs03678558_g1), *TBXAS1*
55
56 (Hs01096058_s1) and *GAPDH* (Hs99999905_m1).
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 *Comparative genomic hybridization (CGH) array analysis*
8

9 We used our previously published, genome-wide, CGH array data in a cohort of NAC,
10 ACA, and ACC.⁸ The *LINC100271* site was scanned manually for its copy number status using
11 Nexus software.
12
13
14

15
16
17
18
19 *Statistical and data analysis*
20

21 LncRNA expression profiles of ACC samples were compared with NAC and ACA
22 samples. The Gaussian linear model was used to calculate *P*-values, and false discovery rates
23 (FDRs) were calculated using the Benjamini-Hochberg method for each lncRNA. LncRNAs with
24 a log₂ fold change ≥ 2 and an FDR < 0.05 were defined as differentially expressed lncRNAs.
25
26 Differentially expressed lncRNAs were mapped to their associated gene names, and then a gene
27 set enrichment analysis (GSEA) was performed on these genes. An in-house R package,
28 OmicPath (v 0.1) was used to perform the GSEA to discover potential KEGG pathway
29 associations for each set of differentially expressed lncRNAs. Pathways with a *P*-value < 0.05
30 were considered statistically significant. Survival curves were plotted using the Kaplan-Meier
31 methods, and differences in survival rates were determined using the log-rank test. These
32 statistical analyses were done with GraphPad Software with *P* < 0.05 considered statistically
33 significant.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 The ACC cohort from the project database of the Cancer Genome Atlas (TCGA)
51 (<https://tcga-data.nci.nih.gov/tcga/>) which included 79 patients with *HOTTIP*, *CHL1*, *HOXA11*-
52 *AS1*, *CRNDE*, *LINC00271*, *FAM211A-AS1* and *TBXAS1* expression data, as well as follow-up
53 information, were used to study the prognostic importance of lncRNAs. For the overall survival
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 analysis, two groups were defined based on the lncRNA expression levels in the primary tumor.
5
6 Those with a lncRNA level ranked in the top half were classified into the high expression group
7
8 and the rest into the low expression group based on the median value.
9

10
11 The gene expression profiles of ACC samples deposited in the TCGA project database
12
13 were analyzed to compare expression patterns in tumors with high ($n = 39$) vs. low *LINC100271*
14
15 expression ($n = 40$). The downloaded data consisted of quantified gene expression data that were
16
17 further processed using the DESeq2 package.¹⁵ The differentially expressed genes were annotated,
18
19 and GSEA analysis was performed using the clusterProfiler package.¹⁶
20
21
22
23
24
25

26 **Results**

27 *Differentially expressed lncRNAs in ACC versus NAC*

28
29
30
31 Unsupervised hierarchical and heat map clustering showed distinct clustering of ACC
32
33 samples compared with NAC and ACA samples (Fig. 1). In these samples, 874 lncRNAs were
34
35 differentially expressed in ACC compared with NAC, of which 409 were upregulated, and 465
36
37 were downregulated. The 874 differentially expressed lncRNAs corresponded to 330 annotated
38
39 lncRNA genes. Among the upregulated lncRNAs, the greatest log₂ fold change was 8.5 for an
40
41 unannotated lncRNA gene, and *RAD50* was the greatest upregulated, annotated lncRNA gene
42
43 with a log₂ fold change of 6.1. Among the downregulated lncRNAs, the greatest log₂ fold
44
45 change was 8.3 for an unannotated lncRNA gene and 6.4 for *HAND2*, the greatest downregulated
46
47 annotated lncRNA gene; of these, 183 differently expressed lncRNAs had established functions
48
49 in cancer development and cancer progression. Selected carcinogenesis-related lncRNAs are
50
51 summarized in Table 2.
52
53
54
55
56

57
58 To test the validity of the microarray findings, seven lncRNAs (*HOTTIP*, *CHL1*,
59
60 *HOXA11-AS1*, *CRNDE*, *LINC00271*, *FAM211A-AS1* and *TBXAS1*) were selected among the
61
62
63
64
65

1
2
3
4 carcinogenesis-related, differentially expressed lncRNAs, and their expression was analyzed by
5
6 TaqMan qRT-PCR. The validation cohort included 19 ACC samples and 5 NAC samples.
7
8 *HOTTIP*, *HOXA11-AS1* and *CRNDE* were overexpressed in ACC ($P < 0.05$) and confirmed by
9
10 TaqMan qRT-PCR in the validation cohort ($P < 0.05$; Fig. 2). Expression of *LINC00271*,
11
12 *FAM211A-AS1* and *TBXAS1* was downregulated in ACC ($P < 0.05$) and also by TaqMan qRT-
13
14 PCR ($P < 0.05$) (Fig 2). The microarray result for *CHLI* was not confirmed in the validation
15
16 cohort. Upregulated expression of *CHLI* was identified in the microarray analysis ($P < 0.05$)
17
18 while *CHLI* was found not to be upregulated by TaqMan qRT-PCR in the validation cohort.
19
20
21
22
23
24
25

26 *Differentially expressed lncRNAs in ACC versus ACA*

27

28
29 When comparing ACC with ACA, 1076 lncRNAs were differentially expressed, of which
30
31 780 were upregulated, and 296 were downregulated. The 1,076, differentially expressed lncRNAs
32
33 corresponded to 376 annotated lncRNA genes. Among the upregulated lncRNAs, the greatest
34
35 log₂ fold change was 8.2 for an unannotated lncRNA and 7.0 for *NKAIN4*, the greatest
36
37 upregulated annotated lncRNA. Among the downregulated lncRNAs, the greatest log₂ fold
38
39 change was 7.1 for an unannotated lncRNA gene and 6.9 for *SSTR5*, the greatest downregulated
40
41 annotated lncRNA.
42
43
44

45
46 There was overlap in 206 lncRNAs as they were downregulated in ACC compared to
47
48 NAC and in ACC compared to ACA, and 355 lncRNAs overlapped as they were upregulated in
49
50 ACC compared to NAC and ACA (Fig. 3).
51
52
53
54

55 *Differentially expressed lncRNAs in ACA versus NAC*

56
57
58
59
60
61
62
63
64
65

1
2
3
4 Unsupervised hierarchical and heat map clustering showed that NAC samples clustered
5
6 together with ACA samples (Fig. 1). Only 10 lncRNAs were differentially expressed in ACA
7
8 compared with NAC.
9

10 11 12 13 14 *Functional pathway analysis*

15
16 KEGG pathway analysis of the differentially expressed and annotated lncRNAs in ACC
17
18 compared with NAC and in ACC compared with ACA was performed to understand the biologic
19
20 relevance of these lncRNAs. Twenty-one pathways were significantly enriched in ACC versus
21
22 ACA and 29 pathways were significantly enriched in ACC versus NAC (Tables 3 and 4). Twelve
23
24 of the altered 21 pathways were common to the comparison of ACC versus ACA and ACC
25
26 versus NAC. The KEGG pathways common to both comparisons included ‘Transcriptional
27
28 misregulation in cancer’ and ‘ECM-receptor interaction’.
29
30
31
32
33
34
35

36 *Prognostic lncRNAs in ACC*

37
38 Using the survival data of the ACC TCGA cohort, the prognostic significance of
39
40 *HOTTIP*, *HOXA11-AS1*, *CRNDE*, *LINC00271*, *FAM211A-AS1* and *TBXAS1* was analyzed. Only
41
42 *LINC00271* expression (Fig. 4A) was found to be associated with prognosis. *LINC00271*
43
44 expression levels were positively associated with survival time (Fig. 4B). Median survival time
45
46 for the low-*LINC00271* expression group ($n = 40$) was 4.9 years, whereas it was not reached for
47
48 the high-*LINC00271* expression group ($n = 39$) ($P < 0.019$) (Fig 4C). Student’s t-tests
49
50 demonstrated that *LINC00271* expression levels of stage I tumors were greater than those of stage
51
52 IV tumors ($P < 0.006$).
53
54
55
56
57
58
59

60 *Identification of LINC00271-associated biologic pathways by Gene Set Enrichment Analysis*

1
2
3
4 To identify *LINC00271*-associated biologic pathways, GSEA was performed using high
5
6 throughput, RNA-sequencing data from the TCGA ACC cohort. Among the GO gene sets, the
7
8 WNT signaling pathway, cell cycle, chromosome segregation, and tissue morphogenesis were
9
10 found to be statistically associated with low *LINC00271* expression in the ACC TCGA cohort
11
12 (Fig. 5), suggesting that *LINC00271* may be involved in ACC development and/or progression
13
14 through the above cancer-associated signaling pathways.
15
16
17
18
19
20

21 *LINC00271* copy number alterations

22

23 We performed an analysis of the *LINC00271* chromosomal locus 6q23.3 using genome-
24
25 wide. CGH array data that were generated previously in a cohort of NAC, ACA, and ACC¹⁰ to
26
27 examine whether the *LINC00271* site demonstrated any copy number alterations to explain its
28
29 downregulated expression in ACC. One of 11 NAC samples demonstrated a deletion at 6q23.3,
30
31 whereas 2 of 18 ACA samples demonstrated deletions at 6q23.3, and two other ACA samples
32
33 demonstrated amplifications at 6q23.3. The *LINC00271* locus appeared to be the most unstable
34
35 in ACCs, with 4 of 19 ACC samples demonstrating deletions, and 4 of 19 ACC samples
36
37 demonstrating amplifications of 6q23.3.
38
39
40
41
42
43
44

45 **Discussion**

46

47 This study demonstrated that NAC, ACA, and ACC have distinct lncRNA expression
48
49 profiles, and that *LINC00271*, which appeared to be involved in biologic pathways commonly
50
51 dysregulated in ACC, may be a prognostic marker in ACC.
52
53
54

55 When compared with NAC, 874 lncRNAs were differentially expressed in ACC, 1076
56
57 lncRNAs were differentially expressed in ACA compared with ACC, and only 10 lncRNAs were
58
59 differentially expressed in ACA vs. NAC. Previously, Glover and colleagues demonstrated that
60
61
62
63
64
65

1
2
3
4 the greatest number of differentially expressed lncRNAs in their study was between ACA and
5
6 NAC (2655 lncRNAs), while 956 lncRNAs were differentially expressed between ACC and
7
8 NAC, and 85 lncRNAs were differentially expressed between ACC and ACA.¹¹ The data of these
9
10 investiagotrs suggested that changes in lncRNA expression could be an early part in the
11
12 pathogenesis of both ACC and ACAs. In contrast, our results are not entirely consistent with their
13
14 findings, because we found only 10 lncRNAs that were differentially expressed between ACA and
15
16 NAC.; this finding is in line with the multistep hypothesis in tumorigenesis that is present in most
17
18 human cancers - progressive genetic/genomic alterations increasing/accumulating from NAC to
19
20 ACA to ACC as described previously in our integrated, genome-wide gene expression, gene
21
22 methylation, microRNA expression, and CGH analysis in human samples from NACs, ACAs,
23
24 and ACCs.⁸ The multistep progression from NAC to ACA to ACC is further supported by our
25
26 finding of 296 lncRNAs differentially expressed between ACA versus ACC and 465 lncRNAs
27
28 differentially expressed between ACC vs. NAC. Overall, we found less differently expressed
29
30 lncRNAs in adrenocortical neoplasms compared to the Glover et al. study¹¹, but we used a more
31
32 stringent cut-off in fold-change to identify differentially expressed lncRNAs, and the NAC
33
34 samples used in our study were not adjacent normal tissue to ACAs.
35
36
37
38
39
40
41
42

43 In the current study, the TCGA ACC dataset was used to screen for prognostic
44
45 significance of differentially expressed lncRNAs. *LINC00271* was found to be associated with
46
47 malignancy; patients with low *LINC00271* expression levels survived a significantly lesser time
48
49 than patients with high *LINC00271* expression levels. Previously, a statistically lesser
50
51 expression of *LINC00271* has been described in invasive breast carcinoma, lung adenocarcinoma,
52
53 kidney renal papillary cell carcinoma, head and neck squamous cell carcinoma, and papillary
54
55 thyroid cancer.¹⁷ In addition, *LINC00271* has been found to be an independent risk factor for
56
57 extrathyroidal extension, lymph node metastasis, advanced tumor stage III/IV, and recurrence in
58
59
60
61
62
63
64
65

1
2
3
4 papillary thyroid cancer.¹⁷ GSEA revealed that genes associated with cell adhesion molecules, the
5
6 TP53 signaling pathway, the JAK/STAT signaling pathway, and the cell cycle were statistically
7
8 enriched in papillary thyroid cancer with a low *LINC00271* expression versus papillary thyroid
9
10 cancer with greater *LINC00271* expression. We also found that genes associated with cell cycle
11
12 were associated with low *LINC00271* expression in the TCGA ACC cohort. Further *LINC00271*
13
14 expression was positively associated with the WNT signaling pathway and chromosome
15
16 segregation which are biologic pathways commonly dysregulated in ACC.^{18,19} Thus, our findings
17
18 and other investigators studies suggest that *LINC00271* could contribute to abnormal activation
19
20 of these pathways in a tumor suppressor manner, however, further mechanistic studies are needed
21
22 to test this hypothesis.
23
24
25
26
27

28
29 Studies have suggested that genes with causal roles in tumorigenesis are often located in
30
31 chromosomal areas with alterations in copy number.^{20,21} Gene expression levels are directly
32
33 dependent on chromosomal aneuploidies in carcinomas.²² The strongest correlations have been
34
35 found between genomic copy number and average, chromosome-wide expression levels, but the
36
37 expression of individual genes has also been associated with genomic copy numbers.²³ LncRNAs
38
39 expression levels have been positively correlated with alterations in copy number as well.^{24,25}
40
41 Therefore, we investigated whether alterations in copy number were present at the *LINC00271*
42
43 chromosomal locus 6q23.3. This region had the greatest alteration in ACC samples with 21% of
44
45 samples demonstrating amplifications and another 21% demonstrating deletions, while only 11%
46
47 of ACA samples had amplifications and another 11% deletions of 6q23.3. The instability of
48
49 6q23.3 might explain the dysregulated expression of *LINC00271* in ACC.
50
51
52
53
54

55
56 In conclusion, ACC has a distinct lncRNA expression profile, and *LINC00271*
57
58 downregulation is appears to be associated with malignancy and may be involved in biologic
59
60 pathways commonly dysregulated in ACC.
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

COI/Disclosure

The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article.

Funding/Support

This work was supported by the intramural research program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health (1ZIABC011275-09).

References

1. Bilmoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. *Cancer* 2008;113:3130-6.
2. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. *Eur J Cancer* 2013;49:2579-86.
3. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. *Ann Surg Oncol* 2010;17:263-70.

- 1
2
3
4 4. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination
5
6 chemotherapy in advanced adrenocortical carcinoma. *N Engl J Med* 2012;366:2189-97.
7
8
- 9 5. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, et al. Molecular
10
11 classification and prognostication of adrenocortical tumors by transcriptome profiling.
12
13 *Clin Cancer Res* 2009;15:668-76.
14
15
- 16 6. Soon PS, Gill AJ, Benn DE, Clarkson A, Robinson BG, McDonald KL, et al. Microarray
17
18 gene expression and immunohistochemistry analyses of adrenocortical tumors identify
19
20 IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. *Endocr Relat*
21
22 *Cancer* 2009;16:573-83.
23
24
25
- 26 7. Rechache NS, Wang Y, Stevenson HS, Killian JK, Edelman DC, Merino M, et al. DNA
27
28 methylation profiling identifies global methylation differences and markers of
29
30 adrenocortical tumors. *J Clin Endocrinol Metab* 2012;97:E1004-13.
31
32
- 33 8. Gara SK, Wang Y, Patel D, Liu-Chittenden Y, Jain M, Boufraquech M, et al. Integrated
34
35 genome-wide analysis of genomic changes and gene regulation in human adrenocortical
36
37 tissue samples. *Nucleic Acids Res* 2015;43:9327-39.
38
39
- 40 9. Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O., et al. Integrated
41
42 genomic characterization of adrenocortical carcinoma. *Nat Genet* 2014;46:607-12.
43
44
- 45 10. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al.
46
47 Comprehensive pan-genomic characterization of adrenocortical carcinoma. *Cancer Cell*
48
49 2016;29:723-36.
50
51
- 52 11. Glover AR, Zhao JT, Ip JC, Lee JC, Robinson BG, Gill AJ, et al. Long noncoding RNA
53
54 profiles of adrenocortical cancer can be used to predict recurrence. *Endocr Relat Cancer*
55
56 2015;22:99-109.
57
58
- 59 12. Li L, Chang HY. Physiological roles of long noncoding RNAs: insight from knockout
60
61
62
63
64
65

- 1
2
3
4 mice. *Trends Cell Biol* 2014;24:594-602.
5
6
7 13. Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in
8
9 cancer. *Genomics Proteomics Bioinformatics* 2016;14:42-54.
10
11 14. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in
12
13 adrenocortical carcinoma. *Am J Surg Pathol* 1989;13:202-6.
14
15 15. Love M, Huber W, Anders S. Moderated estimation of fold change and dispersion for
16
17 RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.
18
19 16. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological
20
21 themes among gene clusters. *OMICS* 2012;16:284-7.
22
23 17. Ma B, Liao T, Wen D, Dong C, Zhou L, Yang S, et al. Long intergenic non-coding RNA
24
25 271 is predictive of a poorer prognosis of papillary thyroid cancer. *Sci Rep* 2016;6:36973.
26
27 18. Roshani L, Fujioka K, Auer G, Kjellman M, Lagercrantz S, Larsson C. Aberrations of
28
29 centrosomes in adrenocortical tumors. *Int J Oncol* 2002;20:1161-5.
30
31 19. Ragazzon B, Libe R, Gaujoux S, Assie G, Fratticci A, Launay P, et al. Transcriptome
32
33 analysis reveals that p53 and b-catenin alterations occur in a group of aggressive
34
35 adrenocortical cancers. *Cancer Res* 2010;70:8276-8281.
36
37 20. Kim TM, Xi R, Luquette LJ, Park RW, Johnson MD, Park PJ. Functional genomic
38
39 analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. *Genome*
40
41 *Res* 2013;23:217-27.
42
43 21. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, et al. Pan-
44
45 cancer patterns of somatic copy number alteration. *Nat Genet* 2013;45:1134-40.
46
47 22. Grade M, Hormann P, Becker S, Hummon AB, Wangsa D, Varma S, et al. Gene
48
49 expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation
50
51 and distinct differences between lymph node-negative and lymph node-positive colon
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

carcinomas. *Cancer Res.* 2007;67:41-56.

23. Ried T, Hu Y, Difilippantonio MJ, Ghadimi BM, Grade M, Camps J. The consequences of chromosomal aneuploidy on the transcriptome of cancer cells. *Biochim Biophys Acta* 2012;1819:784-93.

24. Chen H, Xu J, Hong J, Tang R, Zhang X, Fang JY. Long noncoding RNA profiles identify five distinct molecular subtypes of colorectal cancer with clinical relevance. *Mol Oncol* 2014;8:1393-403.

25. Deng Y, Luo S, Zhang X, Zou C, Yuan H, Liao G, et al. A pan-cancer atlas of cancer hallmark-associated candidate driver lncRNAs. *Mol Oncol* 2018;12:1980-2005.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Tables

Table 1. Clinical features of ACA and ACC patients

	ACA*	ACC [†] included in microarray	ACC in validation cohort
Number of patients	11	9	10
Age (average ± SD)	46 years ± 19	52 years ± 15	47 years ± 14
Sex (female/male)	9/2	7/2	6/4
Tumor size (average ± SD)	3.8 cm ± 1.8	6.7 cm ± 5.9	5.4 cm ± 2.2
Functional Syndrome[‡]	55%	44%	30%
Adrenal hypercortisolism	3	4	3
Primary hyperaldosteronism	3	1	0
Nonfunctioning	6	4	7

* ACA, adrenocortical adenoma

[†] ACC, adrenocortical carcinoma

[‡] Functional status at initial presentation

Table 2. Selected carcinogenesis-related differentially expressed lncRNAs between ACC and NAC

Sequence name	Gene symbol	Regulation	P-value	Log2 fold change	Chromosome	Relationship
ENST00000534886	<i>SRRM4</i>	Up	0.001	5.14	Chr12	Intron sense-overlapping
ENST00000472494	<i>HOTTIP</i>	Up	9.11 x 10 ⁻⁵	5.05	Chr7	Bidirectional
ENST00000514846	<i>GRK6</i>	Up	9.92 x 10 ⁻⁶	4.75	Chr5	Natural antisense
NR_002795	<i>HOXA11</i>	Up	4.61 x 10 ⁻⁵	4.05	Chr7	Bidirectional
NR_045572	<i>CHL1</i>	Up	3.45 x 10 ⁻⁴	4.16	Chr3	Exon sense-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

							overlapping
ENST00000558031	<i>CRNDE</i>	Up	1.30×10^{-5}	2.45	Chr16	Intergenic	
ENST00000502941	<i>HAND2</i>	Down	1.52×10^{-7}	6.35	Chr4	Bidirectional	
ENST00000450445	<i>BNC2</i>	Down	1.36×10^{-6}	5.01	Chr9	Intronic antisense	
ENST00000417354	<i>DNM3</i>	Down	4.46×10^{-6}	3.50	Chr1	Intronic antisense	
NR_029394	<i>TBXAS1</i>	Down	2.15×10^{-4}	2.51	Chr7	Exon sense- overlapping	
NR_026805	<i>LINC00271</i>	Down	3.99×10^{-6}	2.50	Chr6	Bidirectional	
NR_027158.1	<i>FAM211A-AS1</i>	Down	2.96×10^{-3}	2.06	Chr17	Intronic antisense	

Table 3. Statistically significant different KEGG pathways in ACC versus ACA

Pathways	Genes	P-value
Pathways in cancer	<i>ADCY2, RALBP1, CSF2RA, DAPK1, FGF13, GSK3B, BIRC5, ITGA3, MMP9, PTGER3, SLC2A1, TGFB2, PAX8, RUNX1</i>	1.791e-3
Vascular smooth muscle contraction	<i>KCNMB2, ADCY2, KCNMA1, AVPRIA, PRKCQ, PRKG1</i>	3.251e-3
Glucagon signaling pathway	<i>ADCY2, PRKAG2, PGAM2, PHKA2, SLC2A1</i>	5.823e-3
Malaria	<i>ITGAL, TGFB2, THBS4</i>	7.960e-3
Transcriptional misregulation in cancer	<i>HOXA10, HOXA11, MMP9, PAX8, HMGA2, HIST1H3G, RUNX1</i>	8.716e-3
Insulin secretion	<i>KCNMB2, ADCY2, KCNMA1, SLC2A1</i>	1.209e-2
Circadian rhythm	<i>ADCY2, PRKG1, PTGER3</i>	1.266 e-2
Salivary secretion	<i>NPAS2, PRKAG2</i>	1.346 e-2
Cell cycle	<i>ADCY2, KCNMA1, LYZ, PRKG1</i>	1.455 e-2
Colorectal cancer	<i>E2F5, GSK3B, MAD2L1, RBL2, TGFB2</i>	1.522 e-2
FoxO signaling pathway	<i>GSK3B, BIRC5, TGFB2</i>	1.786 e-2
Glycolysis / Gluconeogenesis	<i>S1PR1, PRKAG2, RBL2, BNIP3, TGFB2</i>	2.149 e-2
Ubiquitin mediated proteolysis	<i>PGAM2, ADPGK, FBP2</i>	2.307 e-2
Adipocytokine signaling pathway	<i>UBE2S, UBE2D4, SIAH1, UBE2G2, ITCH</i>	2.367 e-2
Signaling pathways regulating pluripotency of stem cells	<i>PRKAG2, PRKCQ, SLC2A1</i>	2.661 e-2
Bladder cancer	<i>ESRRB, GSK3B, PAX6, POU5F1B, PCGF1</i>	2.762 e-2
Insulin resistance	<i>DAPK1, MMP9</i>	2.841 e-2
RNA degradation	<i>GSK3B, PRKAG2, PRKCQ, SLC2A1</i>	3.180 e-2
ECM-receptor interaction	<i>LSM1, EXOSC10, BTG1</i>	3.605 e-2
Hypertrophic cardiomyopathy (HCM)	<i>SV2C, ITGA3, THBS4</i>	4.385e-2

Note Pathways common to the comparison of ACC versus ACA and ACC versus NAC are written in bold type

Table 4. Statistically significantly different KEGG pathways in ACC versus NAC

Pathways	Genes	P-value
ECM-receptor interaction	<i>COL6A2, SV2C, ITGA3, ITGA9, THBS2</i>	5.329e-4
Circadian rhythm	<i>NPAS2, PRKAG2, BHLHE40</i>	5.596e-4
Vascular smooth muscle contraction	<i>MRVII, KCNMA1, AVPR1A, PRKACB, PRKCQ, PRKG1</i>	7.222e-4
Adipocytokine signaling pathway	<i>IKBKB, PRKAG2, PRKCQ, SLC2A1</i>	1.759e-3
Transcriptional misregulation in cancer	<i>HOXA11, MEIS1, MMP9, UTY, PAX8, HMGA2, HIST1H3G</i>	1.785e-3
Cocaine addiction	<i>GRIN3B, GRM3, PRKACB</i>	3.175e-3
Salivary secretion	<i>KCNMA1, LYZ, PRKACB, PRKG1</i>	5.0121e-3
Glucagon signaling pathway	<i>PRKAG2, PGAM2, PRKACB, SLC2A1</i>	8.511e-3
Glycolysis / Gluconeogenesis	<i>ADH1A, PGAM2, ADPGK</i>	9.687e-3
Insulin resistance	<i>IKBKB, PRKAG2, PRKCQ, SLC2A1</i>	1.161e-2
Nicotine addiction	<i>CHRNA4, GRIN3B</i>	1.345e-2
Proteasome	<i>PSMA3, PSMD7</i>	1.740e-2
Platelet activation	<i>LYN, PRKACB, PRKG1, TBXAS1</i>	1.817e-2
Hypertrophic cardiomyopathy (HCM)	<i>ITGA3, ITGA9, PRKAG2</i>	1.998e-2
Hedgehog signaling pathway	<i>CDON, PRKACB</i>	2.074e-2
Endocrine and other factor-regulated calcium reabsorption	<i>DNM3, PRKACB</i>	2.074e-2
Insulin secretion	<i>KCNMA1, PRKACB, SLC2A1</i>	2.161e-2
Neuroactive ligand-receptor interaction	<i>CHRNA4, GRIN3B, GRM3, AVPR1A, RXFP1, SSTR5, THRB</i>	2.227e-2
Dilated cardiomyopathy	<i>ITGA3, ITGA9, PRKACB</i>	2.602e-2
Morphine addiction	<i>GRK6, PDE4D, PRKACB</i>	2.697e-2
NF-kappa B signaling pathway	<i>IKBKB, LYN, PRKCQ</i>	2.891e-2
Circadian entrainment	<i>PRKACB, PRKG1, CACNA1H</i>	3.094e-2
Regulation of lipolysis in adipocytes	<i>PRKACB, PRKG1</i>	3.273e-2
Long-term depression	<i>LYN, PRKG1</i>	3.900e-2
Focal adhesion	<i>COL6A2, ITGA3, ITGA9, PAK3, THBS2</i>	4.064e-2
T cell receptor signaling pathway	<i>IKBKB, PAK3, PRKCQ</i>	4.110e-2
Longevity regulating pathway – multiple species	<i>PRKAG2, PRKACB</i>	4.584e-2
Renin secretion	<i>KCNMA1, PRKACB</i>	4.584e-2
Renal cell carcinoma	<i>PAK3, SLC2A1</i>	4.946e-2

Note Pathways common to the comparison of ACC versus ACA and ACC versus NAC are written in bold type

1
2
3
4 **Figure legends**
5
6
7
8

9 **Fig 1.** Unsupervised hierarchical clustering and heat map of lncRNA expression between
10 adrenocortical carcinoma (ACC), adrenocortical adenoma (ACA), and normal adrenal cortex
11 (NAC). Each column represents a sample, and each row represents a lncRNA. High relative
12 expression is indicated in yellow and low relative expression in red.
13
14
15
16
17
18
19
20

21 **Fig 2.** TaqMan qRT-PCR validation of lncRNA microarray analysis. Fold-change in comparison
22 of ACC versus NAC, * $P < 0.05$.
23
24
25
26
27

28 **Fig 3.** Venn diagram showing the number of overlapping up- or downregulated lncRNAs in the
29 different comparisons.
30
31
32
33
34
35

36 **Fig 4.** *LINC00271* expression and prognosis. A, Distribution of *LINC00271* expression of ACC
37 samples from the TCGA dataset. Red points were defined as low-*LINC00271* expression group
38 and black points were defined as high-*LINC00271* expression group. B, *LINC00271* expression is
39 positively correlated to survival time (Pearson correlation coefficient = 0.50). C, Kaplan-Meier
40 plot of overall survival in the TCGA the ACC cohort is shown according to *LINC00271*
41 expression level (low vs. high).
42
43
44
45
46
47
48
49
50
51
52

53 **Fig 5.** *LINC00271*-associated biologic signaling pathways. Based on the TCGA dataset, GSEA
54 showed that genes associated with WNT signaling pathway, cell cycle, chromosome segregation
55 and tissue morphogenesis were statistically enriched in lower *LINC00271* versus greater
56 *LINC00271* expressing ACCs. FDR, false discovery rate; NES, normalized enrichment score.
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Discussion

[Click here to view linked References](#)

1
2
3
4
5 Discussion of Paper Number 22
6
7
8
9

10 ADRENOCORTICAL TUMORS HAVE A DISTINCT
11
12
13 LONG NON-CODING RNA EXPRESSION PROFILE AND
14
15
16 LINC00271 IS A PROGNOSTIC MARKER IN
17
18
19 ADRENOCORTICAL CARCINOMA
20
21
22
23

24 DISCUSSANT
25
26
27
28

29 DR. XAVIER KEUTGEN (Chicago, IL):
30
31

32 First of all, did you look at LINC00271 expression
33
34
35 in your cell lines?
36
37
38
39

40 CLOSING DISCUSSANT
41
42
43
44

45 DR. FLORYNE O. BUIHAND: Yes, we also
46
47
48 looked at LINC00271 expression in cell lines, and
49
50
51 it is expressed. We also tried to knock it down;
52
53
54 Unfortunately, that did not work.
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6 DISCUSSANT
7
8
9

10 DR. XAVIER KEUTGEN (Chicago, IL):
11

12 That would have been my next question because that
13
14 may help you find out if it truly has an impact
15
16 on the Wnt pathway, but it's basically
17
18 downregulated as far as you could tell. Good.
19
20
21
22

23
24 Then the second question is, what do we
25
26 do with this? Should this change our diagnostic
27
28 or therapeutic approach?
29
30
31

32 CLOSING DISCUSSANT
33
34
35
36

37 DR. FLORYNE O. BUIHAND: Obviously,
38
39 the study is not powered adequately to say this
40
41 is really an excellent prognostic factor. So it
42
43 needs more study before we can actually
44
45 incorporate it in the current treatment
46
47
48 protocols.
49
50
51
52
53
54
55

56 DISCUSSANT
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6 DR. MARK COHEN (Ann Arbor, MI): How
7
8 confident are you that this is really a marker for
9
10 malignancy given that only 4 out of 19 of your
11
12 cancers showed alterations in the long non-coding
13
14 RNA and a certain percentage of adenomas do as
15
16 well.
17
18
19
20
21
22

23
24 CLOSING DISCUSSANT
25
26
27
28

29 DR. FLORYNE O. BUIHAND: Obviously,
30
31 we only had to look at the copy number status to
32
33 see if we could find an explanation for the
34
35 dysregulated expression. Those numbers are low,
36
37 so we cannot be certain that it is really due to
38
39 dysregulated copy number status. But I do think
40
41 that we have shown with this work that LINC00271
42
43 expression is correlated and associated with
44
45 malignancy and survival.
46
47
48
49
50
51
52
53
54
55

56 DISCUSSANT
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6 DR. EMAD KANDIL (New Orleans, LA): The
7
8 first question is about the design of the study.
9
10 You decided to do the microRNA-seq on your
11
12 specimens and then went back to the TCGA database.
13
14 Usually, you do the bioinformatic analysis in the
15
16 TCGA database, identify a panel, and then go back
17
18 to your specimens and try to find this. I wonder
19
20 why you decided to do it the other way around.
21
22
23
24
25

26
27 You had the seven genes or seven LINC
28
29 RNAs, and then you decided to just focus on the
30
31 LINC00271. I wonder how that happened. Why not
32
33 a panel? Specifically, I think if you are
34
35 looking at prognosis, the panel would be more
36
37 informative than just trying to focus on one.
38
39
40
41
42
43
44

45 CLOSING DISCUSSANT
46
47
48
49

50
51 DR. FLORYNE O. BUIHAND: To address
52
53 your first question, I think we could have gone
54
55 back from the high throughput analysis that we did
56
57 with the microarray. We started with that, and
58
59
60
61
62
63
64
65

1
2
3
4
5 then went on to have a look at the TCGA database,
6
7
8 and we have could have gone back to our own
9
10 samples. But, unfortunately, I don't think that
11
12 we have enough samples to actually make stronger
13
14 conclusions than using the TCGA data set.
15
16
17

18
19 Regarding the second part of your
20
21 question, I think I forgot to mention that we did
22
23 have a look at all those six validated LINC RNAs,
24
25 whether they had prognostic significance, and we
26
27 only found prognostic significance for
28
29 LINC00271. So the other five did not have any
30
31 prognostic significance.
32
33
34
35
36
37
38
39

40 DISCUSSANT
41
42
43
44

45 DR. MICHAEL DEMEURE (Newport Beach,
46
47 CA): TCGA data are actually slanted toward early
48
49 resectable lesions. Those are the operative
50
51 samples, for the most part. So as you added it
52
53 to your multi-step progression, was there a
54
55 difference between localized and metastatic
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5 adrenal cancers in terms of the long non-coding
6
7
8 RNA?
9

10
11 I'm interested in if you are
12
13 hypothesizing that you are seeing progression
14
15 from adenoma to carcinoma. Given the TCGA is
16
17 really slanted toward resected operative
18
19 samples, and thus by definition earlier stage
20
21 tumors, do you have a cohort of stage 4 disease?
22
23
24 And could you link continuation of that
25
26 progression with the long non-coding RNA?
27
28
29
30
31
32
33

34
35 CLOSING DISCUSSANT
36
37
38
39

40 DR. FLORYNE O. BUIHAND: Thank you so
41
42 much for the excellent suggestion. Basically,
43
44 we concluded on our limited sample set that there
45
46 is a stepwise progression, and it would be really
47
48 good to follow up on that finding. But you are
49
50 correct, we cannot really elaborate on that,
51
52 given the fact that the TCGA database only has
53
54 resectable samples.
55
56
57
58
59
60
61
62
63
64
65

TOC Statement

[Click here to view linked References](#)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

TOC Statement- 19-aes-22

Adrenocortical carcinoma (ACC) has a distinct lncRNA expression profile and LINC00271 is a prognostic marker in ACC. The importance of this finding is that LINC00271 may serve as a potential predictor for poor clinical outcomes.